# Official Journal C 351/2013

| | ISSN 1977-091X
  doi:10.3000/1977091X.C_2013.351.eng |
| --- | --- |
| Official Journal
  of the European Union | C 351 |
| | |
| English edition | Information and Notices | Volume 5630 November 2013 |

ISSN 1977-091X

doi:10.3000/1977091X.C_2013.351.eng

Official Journal

of the European Union

C 351

English edition

Information and Notices

Volume 5630 November 2013

---

| Notice No | Contents | page |
| --- | --- | --- |
| | IV   Notices |
| | NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | Council |
| 2013/C 351/01 | EU Action Plan on Drugs 2013-2016 | 1 |
| | European Commission |
| 2013/C 351/02 | Euro exchange rates | 24 |
| | NOTICES FROM MEMBER STATES |
| 2013/C 351/03 | Information communicated by Member States regarding closure of fisheries | 25 |
| 2013/C 351/04 | Information communicated by Member States regarding closure of fisheries | 25 |
| 2013/C 351/05 | Information communicated by Member States regarding closure of fisheries | 26 |

Notice No

Contents

page

IV   Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

Council

2013/C 351/01

EU Action Plan on Drugs 2013-2016

1

European Commission

2013/C 351/02

Euro exchange rates

24

NOTICES FROM MEMBER STATES

2013/C 351/03

Information communicated by Member States regarding closure of fisheries

25

2013/C 351/04

Information communicated by Member States regarding closure of fisheries

25

2013/C 351/05

Information communicated by Member States regarding closure of fisheries

26

| | V   Announcements |
| --- | --- |
| | PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMMON COMMERCIAL POLICY |
| | European Commission |
| 2013/C 351/06 | Notice of initiation of an expiry review and of partial interim reviews and an ex officio partial interim review of the anti-dumping measures applicable to imports of citric acid originating in the People's Republic of China | 27 |
| | PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY |
| | European Commission |
| 2013/C 351/07 | Prior notification of a concentration (Case COMP/M.7018 — Telefónica Deutschland/E-Plus) (
  1
  ) | 37 |
| 2013/C 351/08 | Prior notification of a concentration (Case COMP/M.7023 — Publicis/Omnicom) (
  1
  ) | 38 |
| 2013/C 351/09 | Prior notification of a concentration (Case COMP/M.7068 — Goldman Sachs/Kingdom of Denmark/DONG Energy) — Candidate case for simplified procedure (
  1
  ) | 39 |

V   Announcements

PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMMON COMMERCIAL POLICY

European Commission

2013/C 351/06

Notice of initiation of an expiry review and of partial interim reviews and an ex officio partial interim review of the anti-dumping measures applicable to imports of citric acid originating in the People's Republic of China

ex officio

27

PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY

European Commission

2013/C 351/07

Prior notification of a concentration (Case COMP/M.7018 — Telefónica Deutschland/E-Plus) (
  1
  )

1

37

2013/C 351/08

Prior notification of a concentration (Case COMP/M.7023 — Publicis/Omnicom) (
  1
  )

1

38

2013/C 351/09

Prior notification of a concentration (Case COMP/M.7068 — Goldman Sachs/Kingdom of Denmark/DONG Energy) — Candidate case for simplified procedure (
  1
  )

1

39

| | |
| --- | --- |
| | (1)   Text with EEA relevance |

---

(1)   Text with EEA relevance

1

| EN | |
| --- | --- |

EN

---

IV Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

Council

| 30.11.2013 | EN | Official Journal of the European Union | C 351/1 |
| --- | --- | --- | --- |

30.11.2013

EN

Official Journal of the European Union

C 351/1

---

EU ACTION PLAN ON DRUGS 2013-2016

2013/C 351/01

CONTENTS

Introduction

| 1. | Drug demand reduction |
| --- | --- |

1.

| 2. | Drug supply reduction |
| --- | --- |

2.

| 3. | Coordination |
| --- | --- |

3.

| 4. | International cooperation |
| --- | --- |

4.

| 5. | Information, research, monitoring and evaluation |
| --- | --- |

5.

| Annex 1 — | 15 over-arching indicators for the EU Action Plan on Drugs 2013-2016 (existing reporting mechanisms) |
| --- | --- |

Annex 1 —

| Annex 2 — | Glossary of acronyms |
| --- | --- |

Annex 2 —

Introduction

The use of illicit drugs and the misuse of drugs generally, is a major problem for individuals, families and communities across Europe. Apart from the health and social implications of drug misuse, the illicit drugs market constitutes a major element of criminal activity across European society and, indeed, on a global level.

In December 2012, the Council adopted the EU Drugs Strategy for 2013-2020. The Strategy aims to contribute to a reduction in drug demand and drug supply within the EU. It also aims to reduce the health and social risks and harms caused by drugs through a strategic approach that supports and complements national policies, that provides a framework for coordinated and joint actions and that forms the basis and political framework for EU external cooperation in this field. This will be achieved through an integrated, balanced and evidence-based approach.

The objectives of the Strategy are:

| — | to contribute to a measurable reduction of the use of drugs, of drug dependence and of drug-related health and social risks and harms, |
| --- | --- |

—

to contribute to a measurable reduction of the use of drugs, of drug dependence and of drug-related health and social risks and harms,

| — | to contribute to a disruption of the illicit drugs market and a measurable reduction of the availability of illicit drugs, |
| --- | --- |

—

to contribute to a disruption of the illicit drugs market and a measurable reduction of the availability of illicit drugs,

| — | to encourage coordination through active discourse and analysis of developments and challenges in the field of drugs at EU and international level, |
| --- | --- |

—

to encourage coordination through active discourse and analysis of developments and challenges in the field of drugs at EU and international level,

| — | to further strengthen dialogue and cooperation between the EU and third countries, international organisations and fora on drug issues, |
| --- | --- |

—

to further strengthen dialogue and cooperation between the EU and third countries, international organisations and fora on drug issues,

| — | to contribute to a better understanding of all aspects of the drugs phenomenon and of the impact of interventions in order to provide a sound and comprehensive evidence-base for policies and actions. |
| --- | --- |

—

to contribute to a better understanding of all aspects of the drugs phenomenon and of the impact of interventions in order to provide a sound and comprehensive evidence-base for policies and actions.

This EU Drugs Action Plan, like the EU Drugs Strategy, is based on the fundamental principles of EU law and it upholds the founding values of the Union — respect for human dignity, liberty, democracy, equality, solidarity, the rule of law and human rights. It is also based on the UN conventions that provide the international legal framework to address, inter alia, the use of illicit drugs, as well as on the Universal Declaration on Human Rights.

The Plan sets out the actions that will be implemented to achieve the objectives of the Strategy. Actions are set out under the two policy areas of the Strategy:

| — | drug demand reduction, and |
| --- | --- |

—

drug demand reduction, and

| — | drug supply reduction; |
| --- | --- |

—

drug supply reduction;

and the three cross-cutting themes of the Strategy:

| — | coordination, |
| --- | --- |

—

coordination,

| — | international cooperation, and |
| --- | --- |

—

international cooperation, and

| — | information, research, monitoring and evaluation. |
| --- | --- |

—

information, research, monitoring and evaluation.

Actions are aligned to objectives of the EU Drugs Strategy 2013-2020. In drawing up the actions, account was taken of the need to be evidence-based, scientifically sound, realistic, time-bound and measurable with a clear EU relevance and added value. This Action Plan indicates timetables, responsible parties, indicators and data collection/assessment mechanisms.

Based on existing reporting mechanisms, a number of over-arching indicators are set out in Annex 1. These facilitate the measurement of the overall effectiveness of this EU Drugs Action Plan and do not involve an additional reporting burden. A number of these are referenced, as appropriate, across the Plan. Furthermore, throughout the Plan, indicators are set out that draw on programme, evaluative and other data sources. Utilisation of these indicators is dependent on data collection processes in each Member State or at EU institution level.

In line with the Strategy stipulation that its detailed implementation should be set out in two consecutive Action Plans, this Action Plan covers the four years from 2013 until 2016. A second Action Plan for the period 2017-2020 will be prepared following an external mid-term assessment of the EU Drugs Strategy by 2016 and taking account of any other relevant strategies and evaluations.

1.   Drug demand reduction

Contribute to a measurable reduction in the use of illicit drugs, in problem drug use, in drug dependence and in drug-related health and social harms as well as contributing to a delay in the onset of drug use

| Objective | Action | Timetable | Responsible party | Indicator(s) | Data collection/assessment mechanisms |
| --- | --- | --- | --- | --- | --- |
| 1. | Prevent drug use and, secondly, delay the onset of drug use |

Objective

Action

Timetable

Responsible party

Indicator(s)

Data collection/assessment mechanisms

1.

Prevent drug use and, secondly, delay the onset of drug use

| 1. | Improve the availability and effectiveness of prevention measures that take account of:






  (a) | population risk factors such as age; gender; cultural and social factors; |
| --- | --- | --- |

1.

Improve the availability and effectiveness of prevention measures that take account of:

(a)

population risk factors such as age; gender; cultural and social factors;

| (b) | situational risk factors such as homelessness; drug use in nightlife and recreational settings; the workplace; and driving under the influence of drugs; and |
| --- | --- |

(b)

situational risk factors such as homelessness; drug use in nightlife and recreational settings; the workplace; and driving under the influence of drugs; and

| (c) | individual risk factors such as mental health; problem behaviour and psychosocial development; and other factors known to affect individual vulnerability to drug use such as genetic influences and family circumstances |
| --- | --- |

(c)

individual risk factors such as mental health; problem behaviour and psychosocial development; and other factors known to affect individual vulnerability to drug use such as genetic influences and family circumstances

Ongoing

MS

| — | Overarching indicators 1, 12 |
| --- | --- |

—

Overarching indicators 1, 12

| — | Level of provision at MS level of evidence-based universal and environmental prevention measures |
| --- | --- |

—

Level of provision at MS level of evidence-based universal and environmental prevention measures

| — | Level of provision at MS level of targeted prevention measures, including family- and community-based measures |
| --- | --- |

—

Level of provision at MS level of targeted prevention measures, including family- and community-based measures

| — | Level of provision at MS level of indicated prevention measures |
| --- | --- |

—

Level of provision at MS level of indicated prevention measures

EMCDDA reporting

Reitox national reports

MS reporting on results of measures

| 2. | In addition to the prevention of drug use, strengthen and better target prevention and diversionary measures to delay the age of first use of illicit drugs |
| --- | --- |

2.

In addition to the prevention of drug use, strengthen and better target prevention and diversionary measures to delay the age of first use of illicit drugs

Ongoing

MS

| — | Overarching indicators 1, 5, 12 |
| --- | --- |

—

Overarching indicators 1, 5, 12

| — | Level of provision at MS level of evidence-based prevention and diversionary measures that target young people in family, community, and formal/non-formal education settings |
| --- | --- |

—

Level of provision at MS level of evidence-based prevention and diversionary measures that target young people in family, community, and formal/non-formal education settings

EMCDDA reporting

MS reporting on results of measures

| 3. | Raise awareness of the risks and consequences associated with the use of illicit drugs and other psychoactive substances |
| --- | --- |

3.

Raise awareness of the risks and consequences associated with the use of illicit drugs and other psychoactive substances

Ongoing

MS

COM

EMCDDA

| — | Overarching indicators 5, 12 |
| --- | --- |

—

Overarching indicators 5, 12

| — | Level of awareness in general and youth populations of healthy lifestyles and of the risks and consequences of the use of illicit drugs and other psychoactive substances |
| --- | --- |

—

Level of awareness in general and youth populations of healthy lifestyles and of the risks and consequences of the use of illicit drugs and other psychoactive substances

EMCDDA reporting

Eurobarometer surveys

ESPAD

HBSC

| 4. | Enable a more informed response to the challenge of the misuse of prescribed and ‘over the counter’ opioids and other psychoactive medicines |
| --- | --- |

4.

Enable a more informed response to the challenge of the misuse of prescribed and ‘over the counter’ opioids and other psychoactive medicines

2014-2016

MS

HDG

EMA

EMCDDA

| — | Collation of data by MS on levels and patterns of prescribing of psychoactive medicines by end-2014 |
| --- | --- |

—

Collation of data by MS on levels and patterns of prescribing of psychoactive medicines by end-2014

| — | Number of initiatives that focus on the promotion of appropriate use of prescribed and ‘over the counter’ opioids and other psychoactive medicines |
| --- | --- |

—

Number of initiatives that focus on the promotion of appropriate use of prescribed and ‘over the counter’ opioids and other psychoactive medicines

MS reporting

Report of ALICE RAP project

| 2. | Enhance the effectiveness of drug treatment and rehabilitation, including services for people with co-morbidity, to reduce the use of illicit drugs; problem drug use; the incidence of drug dependency and drug-related health and social risks and harms and to support the recovery and social re/integration of problematic and dependent drug users |
| --- | --- |

2.

Enhance the effectiveness of drug treatment and rehabilitation, including services for people with co-morbidity, to reduce the use of illicit drugs; problem drug use; the incidence of drug dependency and drug-related health and social risks and harms and to support the recovery and social re/integration of problematic and dependent drug users

| 5. | Develop and expand the diversity, availability, coverage and accessibility of comprehensive and integrated treatment services including those which address polydrug use (combined use of illicit and/or licit substances including alcohol) |
| --- | --- |

5.

Develop and expand the diversity, availability, coverage and accessibility of comprehensive and integrated treatment services including those which address polydrug use (combined use of illicit and/or licit substances including alcohol)

Ongoing

MS

| — | Overarching indicators 1, 6, 11 |
| --- | --- |

—

Overarching indicators 1, 6, 11

| — | Extent of the diversity of comprehensive and integrated treatment services at MS level including those which address polydrug use |
| --- | --- |

—

Extent of the diversity of comprehensive and integrated treatment services at MS level including those which address polydrug use

| — | MS data on treatment retention and outcomes |
| --- | --- |

—

MS data on treatment retention and outcomes

EMCDDA reporting

Reitox national reports

EMCDDA Best practice portal

| 6. | Expand the provision of rehabilitation/recovery services with an emphasis on services that:






  (a) | focus on providing a continuum of care through case management and interagency collaboration for individuals; |
| --- | --- | --- |

6.

Expand the provision of rehabilitation/recovery services with an emphasis on services that:

(a)

focus on providing a continuum of care through case management and interagency collaboration for individuals;

| (b) | focus on supporting the social re/integration (including the employability) of problem and dependent drug users; and |
| --- | --- |

(b)

focus on supporting the social re/integration (including the employability) of problem and dependent drug users; and

| (c) | strengthen the diagnostic process and the treatment of psychiatric and physical co-morbidity involving drug use |
| --- | --- |

(c)

strengthen the diagnostic process and the treatment of psychiatric and physical co-morbidity involving drug use

Ongoing

MS

| — | Overarching indicator 11 |
| --- | --- |

—

Overarching indicator 11

MS data on:

| — | Extent of increase in rehabilitation/recovery services adopting case management and inter-agency approaches |
| --- | --- |

—

Extent of increase in rehabilitation/recovery services adopting case management and inter-agency approaches

| — | Extent of increase in the number of programmes, specifically targeted at drug users with co-morbidity, involving partnerships between both mental health and drug rehabilitation/recovery services |
| --- | --- |

—

Extent of increase in the number of programmes, specifically targeted at drug users with co-morbidity, involving partnerships between both mental health and drug rehabilitation/recovery services

| — | Level and duration of abstentions from consumption of illicit and/or licit drugs by people leaving drug treatment |
| --- | --- |

—

Level and duration of abstentions from consumption of illicit and/or licit drugs by people leaving drug treatment

| — | Availability of treatment options to meet needs of people who experience relapses to drug use |
| --- | --- |

—

Availability of treatment options to meet needs of people who experience relapses to drug use

EMCDDA reporting

MS reporting on results of services

| 7. | Ensure that treatment and outreach services incorporate greater access to risk and harm reduction options to lessen the negative consequences of drug use and to substantially reduce the number of direct and indirect drug-related deaths and infectious blood-borne diseases associated with drug use but not limited to HIV and viral hepatitis, as well as sexually transmittable diseases and tuberculosis |
| --- | --- |

7.

Ensure that treatment and outreach services incorporate greater access to risk and harm reduction options to lessen the negative consequences of drug use and to substantially reduce the number of direct and indirect drug-related deaths and infectious blood-borne diseases associated with drug use but not limited to HIV and viral hepatitis, as well as sexually transmittable diseases and tuberculosis

Ongoing

MS

| — | Overarching indicators 2, 3, 4, 11 |
| --- | --- |

—

Overarching indicators 2, 3, 4, 11

| — | Extent of increased availability of and access to evidence-based risk and harm reduction measures in MS |
| --- | --- |

—

Extent of increased availability of and access to evidence-based risk and harm reduction measures in MS

EMCDDA reporting

Reitox national reports

MS reporting on services

| 8. | Scale up the development, availability and coverage of health care measures for drug users in prison and after release with the aim of achieving a quality of care equivalent to that provided in the community |
| --- | --- |

8.

Scale up the development, availability and coverage of health care measures for drug users in prison and after release with the aim of achieving a quality of care equivalent to that provided in the community

Ongoing

MS

| — | Overarching indicator 10 |
| --- | --- |

—

Overarching indicator 10

| — | Availability of services for drug users in prisons and the extent to which prison health care policies and practices incorporate care models comprising best practices in needs assessment and continuity of care for prisoners during imprisonment |
| --- | --- |

—

Availability of services for drug users in prisons and the extent to which prison health care policies and practices incorporate care models comprising best practices in needs assessment and continuity of care for prisoners during imprisonment

| — | Extent of decrease in drug-related physical and mental health problems amongst prisoners |
| --- | --- |

—

Extent of decrease in drug-related physical and mental health problems amongst prisoners

| — | Extent to which prison-based services and community-based services provide continuity of care for prisoners upon release with particular emphasis on avoiding drug overdoses |
| --- | --- |

—

Extent to which prison-based services and community-based services provide continuity of care for prisoners upon release with particular emphasis on avoiding drug overdoses

EMCDDA reporting

Reitox national reports

MS reporting on services

| 3. | Embed coordinated, best practice and quality approaches in drug demand reduction |
| --- | --- |

3.

Embed coordinated, best practice and quality approaches in drug demand reduction

| 9. | Agree and commence the implementation of EU minimum quality standards, that help bridge the gap between science and practice, for:






  (a) | environmental, universal, selective and indicated prevention measures; |
| --- | --- | --- |

9.

Agree and commence the implementation of EU minimum quality standards, that help bridge the gap between science and practice, for:

(a)

environmental, universal, selective and indicated prevention measures;

| (b) | early detection and intervention measures; |
| --- | --- |

(b)

early detection and intervention measures;

| (c) | risk and harm reduction measures; and |
| --- | --- |

(c)

risk and harm reduction measures; and

| (d) | treatment, rehabilitation, social integration and recovery measures |
| --- | --- |

(d)

treatment, rehabilitation, social integration and recovery measures

2014-2016

Council

HDG

MS

COM

EMCDDA

| — | Consensus achieved by MS on minimum quality standards building on previous EU preparatory studies |
| --- | --- |

—

Consensus achieved by MS on minimum quality standards building on previous EU preparatory studies

EMCDDA Best practice portal

COM biennial progress report

2.   Drug supply reduction

Contribute to a measurable reduction of the availability and supply of illicit drugs in the EU

| Objective | Action | Timetable | Responsible party | Indicator(s) | Data collection/assessment mechanisms |
| --- | --- | --- | --- | --- | --- |
| 4. | Enhance effective law enforcement coordination and cooperation within the EU to counter illicit drug activity, in coherence, as appropriate, with relevant actions determined through the EU policy cycle |

Objective

Action

Timetable

Responsible party

Indicator(s)

Data collection/assessment mechanisms

4.

Enhance effective law enforcement coordination and cooperation within the EU to counter illicit drug activity, in coherence, as appropriate, with relevant actions determined through the EU policy cycle

| 10. | Utilise to best effect available intelligence and information-sharing law enforcement instruments, channels and communication tools used to collate and analyse drug-related information |
| --- | --- |

10.

Utilise to best effect available intelligence and information-sharing law enforcement instruments, channels and communication tools used to collate and analyse drug-related information

Ongoing

MS

Europol

Eurojust

COSI

| — | Overarching indicator 7 |
| --- | --- |

—

Overarching indicator 7

| — | Extent of high impact intelligence led and targeted activities, of joint operations, joint investigation teams and cross-border cooperation initiatives focusing on criminal organisations engaged in illicit drug activity |
| --- | --- |

—

Extent of high impact intelligence led and targeted activities, of joint operations, joint investigation teams and cross-border cooperation initiatives focusing on criminal organisations engaged in illicit drug activity

| — | Increased use of Europol’s drug-related information sharing, analysis and expert systems |
| --- | --- |

—

Increased use of Europol’s drug-related information sharing, analysis and expert systems

| — | Results achieved from EMPACT projects and bilateral and multilateral initiatives |
| --- | --- |

—

Results achieved from EMPACT projects and bilateral and multilateral initiatives

EMCDDA reporting

EU agencies reporting

EMPACT driver reports

| 11. | Identify and prioritise the most pressing threats associated with drug-related organised crime |
| --- | --- |

11.

Identify and prioritise the most pressing threats associated with drug-related organised crime

2014

Council

COSI

Europol

MS

COM

| — | EU policy cycle and crime priorities for 2014-2017 in place |
| --- | --- |

—

EU policy cycle and crime priorities for 2014-2017 in place

Council conclusions on EU policy cycle

EU SOCTA

EMPACT evaluation

| 12. | Strengthen CEPOL’s training for law enforcement officers in relation to illicit drug production and trafficking, particularly training methods and techniques:






  (a) | to combat the use of new communication technologies in illicit drug production and trafficking; |
| --- | --- | --- |

12.

Strengthen CEPOL’s training for law enforcement officers in relation to illicit drug production and trafficking, particularly training methods and techniques:

(a)

to combat the use of new communication technologies in illicit drug production and trafficking;

| (b) | to enhance asset confiscation; |
| --- | --- |

(b)

to enhance asset confiscation;

| (c) | to combat money laundering; and |
| --- | --- |

(c)

to combat money laundering; and

| (d) | to detect and dismantle illicit clandestine laboratories and cannabis cultivation sites |
| --- | --- |

(d)

to detect and dismantle illicit clandestine laboratories and cannabis cultivation sites

2014-2016

MS

CEPOL

Europol

COSI

COM

| — | Training needs assessment carried out by end-2014 |
| --- | --- |

—

Training needs assessment carried out by end-2014

| — | Availability and uptake of relevant training courses |
| --- | --- |

—

Availability and uptake of relevant training courses

| — | Number of law enforcement officers trained and effectively deployed as a result |
| --- | --- |

—

Number of law enforcement officers trained and effectively deployed as a result

COM biennial progress report

CEPOL annual report

CEPOL Curricula

EMPACT evaluation

| 13. | Improve counter narcotic activities through strengthening and monitoring the effectiveness of regional information-sharing platforms and regional security-sharing platforms with the aim of disrupting and suppressing emerging threats from changing drug trafficking routes |
| --- | --- |

13.

Improve counter narcotic activities through strengthening and monitoring the effectiveness of regional information-sharing platforms and regional security-sharing platforms with the aim of disrupting and suppressing emerging threats from changing drug trafficking routes

Ongoing

COM

MS

Europol

COSI

Regional information-sharing platforms

Regional security-sharing platforms

| — | Overarching indicator 7 |
| --- | --- |

—

Overarching indicator 7

| — | Number of intelligence led activities leading to the disruption and suppression of drug trafficking routes |
| --- | --- |

—

Number of intelligence led activities leading to the disruption and suppression of drug trafficking routes

| — | Level of information sharing through effective activity of the liaison officer network |
| --- | --- |

—

Level of information sharing through effective activity of the liaison officer network

EMCDDA reporting

Security/information-sharing platforms and evaluation reports

EU SOCTA

EMPACT evaluation

| 14. | Strengthen actions to prevent the diversion of drug precursors and pre-precursors for use in the illicit manufacture of drugs |
| --- | --- |

14.

Strengthen actions to prevent the diversion of drug precursors and pre-precursors for use in the illicit manufacture of drugs

Ongoing

MS

Europol

COM

CUG

COSI

| — | Number of cases and quantity of stopped or seized shipments of precursors intended for illicit use |
| --- | --- |

—

Number of cases and quantity of stopped or seized shipments of precursors intended for illicit use

| — | Results achieved from EMPACT projects |
| --- | --- |

—

Results achieved from EMPACT projects

| — | Use of Pre-Export Notification (PEN) Online System and increased use of the Precursors Incident Communication System (PICS) |
| --- | --- |

—

Use of Pre-Export Notification (PEN) Online System and increased use of the Precursors Incident Communication System (PICS)

| — | Number of joint follow-up meetings and other activities linked to the prevention of the diversion of precursors and pre-precursors |
| --- | --- |

—

Number of joint follow-up meetings and other activities linked to the prevention of the diversion of precursors and pre-precursors

Reports from EU and MS law enforcement agencies

EMPACT evaluation

Driver reports

| 15. | Counter cross-border drug trafficking and improve border security notably at EU seaports, airports and land border crossing points through intensified efforts, including information and intelligence sharing, by relevant law enforcement agencies |
| --- | --- |

15.

Counter cross-border drug trafficking and improve border security notably at EU seaports, airports and land border crossing points through intensified efforts, including information and intelligence sharing, by relevant law enforcement agencies

Ongoing

MS

Europol

CCWP

COSI

| — | Increased number of multi-disciplinary/multi-agency joint operations and cross-border cooperation initiatives |
| --- | --- |

—

Increased number of multi-disciplinary/multi-agency joint operations and cross-border cooperation initiatives

| — | Number of effective memoranda of understanding (MOU) agreed between law enforcement agencies and relevant bodies such as airlines, air express couriers, shipping companies, harbour authorities and chemical companies |
| --- | --- |

—

Number of effective memoranda of understanding (MOU) agreed between law enforcement agencies and relevant bodies such as airlines, air express couriers, shipping companies, harbour authorities and chemical companies

| — | Results achieved from EMPACT projects |
| --- | --- |

—

Results achieved from EMPACT projects

| — | Improved intelligence and information sharing on cross-border drug trafficking utilising, inter alia, available border surveillance systems |
| --- | --- |

—

Improved intelligence and information sharing on cross-border drug trafficking utilising, inter alia, available border surveillance systems

COM biennial progress report

EMPACT evaluation and driver reports

MS reporting

| 16. | Develop and progressively implement key indicators on drug supply by standardising, improving and streamlining data collection in this field, building on currently available data |
| --- | --- |

16.

Develop and progressively implement key indicators on drug supply by standardising, improving and streamlining data collection in this field, building on currently available data

2013-2016

COM

MS

Council

HDG

EMCDDA

Europol

| — | Roadmap developed and agreed on the implementation of key drug supply indicators |
| --- | --- |

—

Roadmap developed and agreed on the implementation of key drug supply indicators

| — | MS agreement reached on key drug supply indicators |
| --- | --- |

—

MS agreement reached on key drug supply indicators

Overview of existing supply data collection in MS

EMCDDA reporting

COM biennial progress report

| 5. | Enhance effective judicial cooperation and legislation within the EU |
| --- | --- |

5.

Enhance effective judicial cooperation and legislation within the EU

| 17. | Strengthen EU judicial cooperation in targeting cross-border drug trafficking, money laundering, and in the confiscation of the proceeds of drug-related organised crime |
| --- | --- |

17.

Strengthen EU judicial cooperation in targeting cross-border drug trafficking, money laundering, and in the confiscation of the proceeds of drug-related organised crime

2013-2016

Council

COM

MS

Eurojust

| — | Adoption and timely implementation of agreed EU measures and legislation on (a) confiscation and recovery of criminal assets; (b) money laundering; (c) approximation of drug trafficking offences and sanctions across the EU |
| --- | --- |

—

Adoption and timely implementation of agreed EU measures and legislation on (a) confiscation and recovery of criminal assets; (b) money laundering; (c) approximation of drug trafficking offences and sanctions across the EU

| — | Increased number of financial investigations and confiscations in relation to the proceeds of drug-related organised crime through EU judicial cooperation |
| --- | --- |

—

Increased number of financial investigations and confiscations in relation to the proceeds of drug-related organised crime through EU judicial cooperation

| — | Timely and effective responses to mutual assistance requests and European Arrest Warrants in relation to illicit drug trafficking |
| --- | --- |

—

Timely and effective responses to mutual assistance requests and European Arrest Warrants in relation to illicit drug trafficking

Eurojust reporting

COM biennial progress report

| 18. | Introduce and adopt new EU legislative measures to address the emergence, use and rapid spread of new psychoactive substances |
| --- | --- |

18.

Introduce and adopt new EU legislative measures to address the emergence, use and rapid spread of new psychoactive substances

2013-2016

COM

Council

HDG

MS

| — | EU legislation in place |
| --- | --- |

—

EU legislation in place

| — | Implementation of EU legislation in MS |
| --- | --- |

—

Implementation of EU legislation in MS

COM biennial progress report

| 19. | Strengthen EU legislation on drug precursors to prevent their diversion without disrupting lawful trade |
| --- | --- |

19.

Strengthen EU legislation on drug precursors to prevent their diversion without disrupting lawful trade

Ongoing

Council

COM

MS

| — | Adoption and implementation of regulations of the European Parliament and of the Council on drug precursors amending both Council Regulation (EC) No 111/2005 and Regulation (EC) No 273/2004 |
| --- | --- |

—

Adoption and implementation of regulations of the European Parliament and of the Council on drug precursors amending both Council Regulation (EC) No 111/2005 and Regulation (EC) No 273/2004

COM biennial progress report

EU annual report on drug precursors

| 20. | Combat the use of certain pharmacologically active substances (as defined in Directive 2011/62/EU) as cutting agents for illicit drugs |
| --- | --- |

20.

Combat the use of certain pharmacologically active substances (as defined in Directive 2011/62/EU) as cutting agents for illicit drugs

Ongoing

MS

COM

EMA

EMCDDA

Europol

| — | Number of seizures of active substances used as cutting agents for illicit drugs |
| --- | --- |

—

Number of seizures of active substances used as cutting agents for illicit drugs

| — | Timely implementation of new EU legislative requirements aimed at securing the supply chain for active substances under Directive 2011/62/EU, the Falsified Medicines Directive |
| --- | --- |

—

Timely implementation of new EU legislative requirements aimed at securing the supply chain for active substances under Directive 2011/62/EU, the Falsified Medicines Directive

Reports from the CCWP and CUG

MS reporting

| 21. | Members States to provide, where appropriate and in accordance with their legal frameworks, alternatives to coercive sanctions (such as education, treatment, rehabilitation, aftercare and social integration) for drug-using offenders |
| --- | --- |

21.

Members States to provide, where appropriate and in accordance with their legal frameworks, alternatives to coercive sanctions (such as education, treatment, rehabilitation, aftercare and social integration) for drug-using offenders

2015

MS

| — | Increased availability and implementation of alternatives to prison for drug-using offenders in the areas of education, treatment, rehabilitation, aftercare and social integration |
| --- | --- |

—

Increased availability and implementation of alternatives to prison for drug-using offenders in the areas of education, treatment, rehabilitation, aftercare and social integration

| — | Increased monitoring, implementation and evaluation of alternatives to coercive sanctions |
| --- | --- |

—

Increased monitoring, implementation and evaluation of alternatives to coercive sanctions

Reitox national reports

| 6. | Respond effectively to current and emerging trends in illicit drug activity |
| --- | --- |

6.

Respond effectively to current and emerging trends in illicit drug activity

| 22. | Identify strategic responses to address the role of new communication technologies and the hosting of associated websites, in the production, marketing, purchasing and distribution of illicit drugs, including controlled new psychoactive substances |
| --- | --- |

22.

Identify strategic responses to address the role of new communication technologies and the hosting of associated websites, in the production, marketing, purchasing and distribution of illicit drugs, including controlled new psychoactive substances

Ongoing

Council

COM

HDG

MS

Europol

COSI

| — | Results achieved from law enforcement actions targeting drug-related crime via the Internet |
| --- | --- |

—

Results achieved from law enforcement actions targeting drug-related crime via the Internet

| — | Increased number of joint operations and cross-border cooperation initiatives |
| --- | --- |

—

Increased number of joint operations and cross-border cooperation initiatives

Progress review of EU policy cycle priorities

EMPACT evaluation and driver reports

MS reporting

Reports from EU agencies

3.   Coordination

Member States and EU to effectively coordinate drugs policy

| Objective | Action | Timetable | Responsible party | Indicator(s) | Data collection/assessment mechanisms |
| --- | --- | --- | --- | --- | --- |
| 7. | Ensure effective EU coordination in the drugs field |

Objective

Action

Timetable

Responsible party

Indicator(s)

Data collection/assessment mechanisms

7.

Ensure effective EU coordination in the drugs field

| 23. | Enhance information sharing between the HDG and other relevant Council Working Groups |
| --- | --- |

23.

Enhance information sharing between the HDG and other relevant Council Working Groups

Ongoing

PRES

Council

EEAS

HDG

| — | Extent to which the EU Drugs Strategy/and Action Plan are taken into account in the programmes of other Council Working Groups including COAFR, COASI, COEST, COLAT and COWEB |
| --- | --- |

—

Extent to which the EU Drugs Strategy/and Action Plan are taken into account in the programmes of other Council Working Groups including COAFR, COASI, COEST, COLAT and COWEB

Council Working Group reporting

| 24. | Each presidency may convene meetings of the National Drugs Coordinators, and of other groupings as appropriate, to consider emerging trends, effective interventions and other policy developments of added value to the EU Drugs Strategy and to MS |
| --- | --- |

24.

Each presidency may convene meetings of the National Drugs Coordinators, and of other groupings as appropriate, to consider emerging trends, effective interventions and other policy developments of added value to the EU Drugs Strategy and to MS

Biannually

PRES

MS

| — | Extent to which National Drug Coordinators’ meeting agenda reflects developments, trends and new insights in policy responses and provides for improved communication and information exchange |
| --- | --- |

—

Extent to which National Drug Coordinators’ meeting agenda reflects developments, trends and new insights in policy responses and provides for improved communication and information exchange

Presidency reporting

| 25. | The HDG will facilitate: (a) monitoring of the implementation of the Action Plan through thematic debates; and (b) an annual dialogue on the state of the drugs phenomenon in Europe |
| --- | --- |

25.

The HDG will facilitate: (a) monitoring of the implementation of the Action Plan through thematic debates; and (b) an annual dialogue on the state of the drugs phenomenon in Europe

| (a) | Biannually |
| --- | --- |

(a)

Biannually

| (b) | Annually |
| --- | --- |

(b)

Annually

PRES

HDG

MS

COM

EMCDDA

Europol

| — | Extent of implementation of the Action Plan |
| --- | --- |

—

Extent of implementation of the Action Plan

| — | Timeliness of dialogue at the HDG on latest drug-related trends and data |
| --- | --- |

—

Timeliness of dialogue at the HDG on latest drug-related trends and data

Presidency reporting

| 26. | Ensure consistency and continuity of MS and EU actions across presidencies to strengthen the integrated, balanced and evidence-based approach to drugs in the EU |
| --- | --- |

26.

Ensure consistency and continuity of MS and EU actions across presidencies to strengthen the integrated, balanced and evidence-based approach to drugs in the EU

Biannually

PRES

PRES Trio

MS

COM

HDG

EMCDDA

Europol

| — | Extent of consistency and continuity of actions across presidencies |
| --- | --- |

—

Extent of consistency and continuity of actions across presidencies

| — | Advancement in implementation of EU Drugs Strategy priorities across presidencies |
| --- | --- |

—

Advancement in implementation of EU Drugs Strategy priorities across presidencies

Presidency reporting

| 27. | Ensure coordination of EU drugs policies and responses, to support international cooperation between the EU, third countries and international organisations |
| --- | --- |

27.

Ensure coordination of EU drugs policies and responses, to support international cooperation between the EU, third countries and international organisations

Ongoing

EEAS

COM

HDG

MS

| — | Level of consistency and coherence in the objectives, expected results and measures foreseen in EU actions on drugs |
| --- | --- |

—

Level of consistency and coherence in the objectives, expected results and measures foreseen in EU actions on drugs

| — | Inclusion of drug-related priorities in strategies of relevant EU bodies |
| --- | --- |

—

Inclusion of drug-related priorities in strategies of relevant EU bodies

| — | Intensified cooperation between the HDG and the geographical/regional working groups, including COAFR, COASI, COEST, COLAT and COWEB |
| --- | --- |

—

Intensified cooperation between the HDG and the geographical/regional working groups, including COAFR, COASI, COEST, COLAT and COWEB

Annual EEAS report to the HDG

COM biennial progress report

| 28. | Achieve a coordinated and appropriate level of resources at EU level and Member State level to fulfil the priorities of the EU Drugs Strategy |
| --- | --- |

28.

Achieve a coordinated and appropriate level of resources at EU level and Member State level to fulfil the priorities of the EU Drugs Strategy

Annually

MS

COM

EEAS

Council

HDG

| — | Overarching indicator 14 |
| --- | --- |

—

Overarching indicator 14

| — | Amount of funding at EU level, and where appropriate, MS level |
| --- | --- |

—

Amount of funding at EU level, and where appropriate, MS level

| — | Extent of coordination on drugs-related financial programmes across Council Working Groups |
| --- | --- |

—

Extent of coordination on drugs-related financial programmes across Council Working Groups

EMCDDA reporting

COM biennial progress report

| 8. | Ensure effective coordination of drug-related policy at national level |
| --- | --- |

8.

Ensure effective coordination of drug-related policy at national level

| 29. | Coordinate actions on drugs policy between government departments/ministries and relevant agencies at MS level and ensure appropriate multi-disciplinary representation on, or input to, HDG delegations |
| --- | --- |

29.

Coordinate actions on drugs policy between government departments/ministries and relevant agencies at MS level and ensure appropriate multi-disciplinary representation on, or input to, HDG delegations

Ongoing

MS

| — | Overarching indicator 14 |
| --- | --- |

—

Overarching indicator 14

| — | Effectiveness of a horizontal drug policy coordination mechanism at MS level |
| --- | --- |

—

Effectiveness of a horizontal drug policy coordination mechanism at MS level

| — | Number of cross-cutting actions in drug demand and supply reduction at Member State level |
| --- | --- |

—

Number of cross-cutting actions in drug demand and supply reduction at Member State level

EMCDDA reporting

Reitox national reporting

COM Biennial Progress Report

MS reporting

| 9. | Ensure the participation of civil society in drugs policy |
| --- | --- |

9.

Ensure the participation of civil society in drugs policy

| 30. | Promote and support dialogue with, and involvement of, civil society and the scientific community in the development and implementation of drugs policies at MS and EU levels |
| --- | --- |

30.

Promote and support dialogue with, and involvement of, civil society and the scientific community in the development and implementation of drugs policies at MS and EU levels

Ongoing

MS

COM

HDG

PRES

| — | Timely dialogues between EU Civil Society Forum on Drugs and the HDG during each Presidency period |
| --- | --- |

—

Timely dialogues between EU Civil Society Forum on Drugs and the HDG during each Presidency period

| — | Engagement of EU Civil Society Forum in reviewing implementation of the EU Drugs Action Plan |
| --- | --- |

—

Engagement of EU Civil Society Forum in reviewing implementation of the EU Drugs Action Plan

| — | Level of involvement of civil society in MS and EU drugs policy development and implementation with particular regard to the involvement of drug users, clients of drug-related services and young people |
| --- | --- |

—

Level of involvement of civil society in MS and EU drugs policy development and implementation with particular regard to the involvement of drug users, clients of drug-related services and young people

| — | Timely dialogue between the scientific community (natural and social sciences, including neuroscience and behavioural research) and the HDG |
| --- | --- |

—

Timely dialogue between the scientific community (natural and social sciences, including neuroscience and behavioural research) and the HDG

COM biennial progress report

Feedback from EU Civil Society Forum on Drugs and from civil society representatives at MS level

MS reporting

Feedback from scientific community through the EMCDDA Scientific Committee

4.   International Cooperation

Strengthen dialogue and cooperation between the EU and third countries and international organisations on drugs issues in a comprehensive and balanced manner

| Objective | Action | Timetable | Responsible party | Indicator(s) | Data collection/assessment mechanisms |
| --- | --- | --- | --- | --- | --- |
| 10. | Integrate the EU Drugs Strategy within the EU's overall foreign policy framework as part of a comprehensive approach that makes full use of the variety of policies and diplomatic, political and financial instruments at the EU's disposal in a coherent and coordinated manner |

Objective

Action

Timetable

Responsible party

Indicator(s)

Data collection/assessment mechanisms

10.

Integrate the EU Drugs Strategy within the EU's overall foreign policy framework as part of a comprehensive approach that makes full use of the variety of policies and diplomatic, political and financial instruments at the EU's disposal in a coherent and coordinated manner

| 31. | Ensure policy coherence between the internal and external aspects of the EU drugs policies and fully integrate drugs issues within the political dialogues and framework agreements between the EU and its partners and in the EU advocacy on global issues or challenges |
| --- | --- |

31.

Ensure policy coherence between the internal and external aspects of the EU drugs policies and fully integrate drugs issues within the political dialogues and framework agreements between the EU and its partners and in the EU advocacy on global issues or challenges

Ongoing

COM

EEAS

PRES

HDG

MS

| — | Overarching indicator 13 |
| --- | --- |

—

Overarching indicator 13

| — | Drug policy priorities increasingly reflected in EU’s external policies and actions |
| --- | --- |

—

Drug policy priorities increasingly reflected in EU’s external policies and actions

| — | Inclusion of drug-related priorities in EU strategies with third countries and regions |
| --- | --- |

—

Inclusion of drug-related priorities in EU strategies with third countries and regions

| — | Number of agreements, strategy papers, action plans in place |
| --- | --- |

—

Number of agreements, strategy papers, action plans in place

EEAS reporting

Mid-term review of EU Drugs Strategy

COM biennial progress report

| 32. | Ensure that the policy priorities and the balance between demand and supply reduction are well reflected in policy options and in the programming and implementation of external assistance, particularly in source and transit countries, through projects involving:






  (a) | development of integrated, balanced and evidence-based drug policies; |
| --- | --- | --- |

32.

Ensure that the policy priorities and the balance between demand and supply reduction are well reflected in policy options and in the programming and implementation of external assistance, particularly in source and transit countries, through projects involving:

(a)

development of integrated, balanced and evidence-based drug policies;

| (b) | supply reduction; |
| --- | --- |

(b)

supply reduction;

| (c) | the prevention of the diversion of drug precursors and pre-precursors; |
| --- | --- |

(c)

the prevention of the diversion of drug precursors and pre-precursors;

| (d) | drug demand reduction; and |
| --- | --- |

(d)

drug demand reduction; and

| (e) | alternative development measures |
| --- | --- |

(e)

alternative development measures

Ongoing

COM

MS

EEAS

| — | Extent to which EU’s drug policy priorities, especially the balance between demand and supply reduction, are reflected in funded priorities and projects |
| --- | --- |

—

Extent to which EU’s drug policy priorities, especially the balance between demand and supply reduction, are reflected in funded priorities and projects

| — | Level of implementation of coordinated actions in action plans between the EU and third countries and regions |
| --- | --- |

—

Level of implementation of coordinated actions in action plans between the EU and third countries and regions

| — | Number of third country national strategies and action plans that incorporate integrated drug policies |
| --- | --- |

—

Number of third country national strategies and action plans that incorporate integrated drug policies

COM biennial progress report

EEAS reporting on programm-ing

Monitoring and evaluation by MS

| 33. | Improve capacity and strengthen the role of EU Delegations to enable them to proactively engage on drugs policy issues |
| --- | --- |

33.

Improve capacity and strengthen the role of EU Delegations to enable them to proactively engage on drugs policy issues

2013-2016

EEAS

COM

MS

| — | Relevant expertise, training and policy guidance provided to EU Delegations |
| --- | --- |

—

Relevant expertise, training and policy guidance provided to EU Delegations

| — | Regional networking among EU Delegations on drug issues enhanced |
| --- | --- |

—

Regional networking among EU Delegations on drug issues enhanced

| — | Coordination with MS enhanced |
| --- | --- |

—

Coordination with MS enhanced

EEAS reporting on EU Delegations

| 34. | Ensure an appropriate level of EU and MS funding and expertise to further strengthen and support third countries' efforts in addressing and preventing illicit drug crop cultivation, through rural development measures, in order to deal with the challenges to public health, safety and security |
| --- | --- |

34.

Ensure an appropriate level of EU and MS funding and expertise to further strengthen and support third countries' efforts in addressing and preventing illicit drug crop cultivation, through rural development measures, in order to deal with the challenges to public health, safety and security

Ongoing

MS

EEAS

COM

| — | Number of third country national policies, strategies and action plans that incorporate integrated approaches to the problem of illicit drug crop cultivation |
| --- | --- |

—

Number of third country national policies, strategies and action plans that incorporate integrated approaches to the problem of illicit drug crop cultivation

| — | Improvements in human development indicators in drug-cultivating areas |
| --- | --- |

—

Improvements in human development indicators in drug-cultivating areas

| — | Number of rural development projects and programmes funded by the EU and MS in regions where illicit crop cultivation is taking place, or in regions at risk of illicit crop cultivation |
| --- | --- |

—

Number of rural development projects and programmes funded by the EU and MS in regions where illicit crop cultivation is taking place, or in regions at risk of illicit crop cultivation

| — | Reported local decrease in illicit drug crop cultivation in the long term |
| --- | --- |

—

Reported local decrease in illicit drug crop cultivation in the long term

EU and MS project and programme monitoring and evaluation systems and reports

UNDP human development reports

Third country reports

| 35. | Promote and implement the EU approach to alternative development (consistent with the EU Drugs Strategy 2013-2020; the EU Approach to Alternative Development and the United Nations Guiding Principles on Alternative Development 2013) in co-operation with third countries, taking into account human rights, human security and specific framework conditions, including:






  (a) | incorporating alternative development into the broader agenda of Member States, encouraging third countries that wish to do so to integrate alternative development into their national strategies; |
| --- | --- | --- |

35.

Promote and implement the EU approach to alternative development (consistent with the EU Drugs Strategy 2013-2020; the EU Approach to Alternative Development and the United Nations Guiding Principles on Alternative Development 2013) in co-operation with third countries, taking into account human rights, human security and specific framework conditions, including:

(a)

incorporating alternative development into the broader agenda of Member States, encouraging third countries that wish to do so to integrate alternative development into their national strategies;

| (b) | contributing to initiatives that aim to reduce poverty, conflict and vulnerability by supporting sustainable, legal and gender sensitive livelihoods for peoplewho were previously, or are currently, involved in illicit drug production |
| --- | --- |

(b)

contributing to initiatives that aim to reduce poverty, conflict and vulnerability by supporting sustainable, legal and gender sensitive livelihoods for peoplewho were previously, or are currently, involved in illicit drug production

Ongoing

MS

COM

EEAS

| — | Number of third country national policies, strategies and action plans that incorporate:






  — | integrated approaches to the problem of illicit drug cultivation, and |
| --- | --- | --- |

—

Number of third country national policies, strategies and action plans that incorporate:

—

integrated approaches to the problem of illicit drug cultivation, and

| — | effectively organised alternative development initiatives |
| --- | --- |

—

effectively organised alternative development initiatives

| — | Number of evaluated projects that demonstrate positive outcomes relating to sustainable, legal and gender sensitive livelihoods |
| --- | --- |

—

Number of evaluated projects that demonstrate positive outcomes relating to sustainable, legal and gender sensitive livelihoods

| — | Improvements in human development indicators |
| --- | --- |

—

Improvements in human development indicators

Third countries’ implementation reports of national drugs strategies

EU and MS project and programme monitoring and evaluation system and report

UNDP human development reports

| 36. | Support third countries, including civil society in those countries, to develop and implement risk and harm reduction initiatives particularly where there is a growing threat of transmission of drug-related blood-borne viruses associated with drug use including but not limited to HIV and viral hepatitis, as well as sexually transmittable diseases and tuberculosis |
| --- | --- |

36.

Support third countries, including civil society in those countries, to develop and implement risk and harm reduction initiatives particularly where there is a growing threat of transmission of drug-related blood-borne viruses associated with drug use including but not limited to HIV and viral hepatitis, as well as sexually transmittable diseases and tuberculosis

Ongoing

MS

COM

EEAS

| — | Number and quality of risk and harm reduction initiatives developed |
| --- | --- |

—

Number and quality of risk and harm reduction initiatives developed

| — | Prevalence of drug-related deaths in third countries and drug-related blood-borne viruses including but not limited to HIV and viral hepatitis, as well as sexually transmittable diseases and tuberculosis |
| --- | --- |

—

Prevalence of drug-related deaths in third countries and drug-related blood-borne viruses including but not limited to HIV and viral hepatitis, as well as sexually transmittable diseases and tuberculosis

Third country reports

COM biennial progress report

WHO reports

| 37. | Support third countries to tackle drug-related organised crime, including drug trafficking, by:






  (a) | intelligence sharing and the exchange of best practices; |
| --- | --- | --- |

37.

Support third countries to tackle drug-related organised crime, including drug trafficking, by:

(a)

intelligence sharing and the exchange of best practices;

| (b) | strengthening counter-narcotics capacity and developing expertise of source and transit countries; |
| --- | --- |

(b)

strengthening counter-narcotics capacity and developing expertise of source and transit countries;

| (c) | working with international partners to tackle the enablers of drug trafficking such as corruption, weak institutions, poor governance and lack of financial regulatory controls; |
| --- | --- |

(c)

working with international partners to tackle the enablers of drug trafficking such as corruption, weak institutions, poor governance and lack of financial regulatory controls;

| (d) | strengthening cooperation in the field of asset identification and recovery, in particular through the creation of dedicated national platforms; and |
| --- | --- |

(d)

strengthening cooperation in the field of asset identification and recovery, in particular through the creation of dedicated national platforms; and

| (e) | intensifying regional and intra-regional cooperation |
| --- | --- |

(e)

intensifying regional and intra-regional cooperation

Ongoing

MS

EEAS

COM

Europol

| — | Number and effectiveness of projects and programmes |
| --- | --- |

—

Number and effectiveness of projects and programmes

| — | Sustained reduction in drug trafficking |
| --- | --- |

—

Sustained reduction in drug trafficking

COM biennial progress report

MS reporting

Europol reporting

EEAS reporting

UNODC annual world drug report

| 38. | Reinforce cooperation and update and implement dialogues, declarations and EU Drugs Action Plans with partners, including:






  (a) | acceding countries, candidate countries and potential candidates; |
| --- | --- | --- |

38.

Reinforce cooperation and update and implement dialogues, declarations and EU Drugs Action Plans with partners, including:

(a)

acceding countries, candidate countries and potential candidates;

| (b) | European Neighbourhood Policy countries; |
| --- | --- |

(b)

European Neighbourhood Policy countries;

| (c) | United States of America, the Russian Federation; |
| --- | --- |

(c)

United States of America, the Russian Federation;

| (d) | other countries or regions of priority notably:






  — | Afghanistan and Pakistan, |
| --- | --- | --- |

(d)

other countries or regions of priority notably:

—

Afghanistan and Pakistan,

| — | Central Asian republics, |
| --- | --- |

—

Central Asian republics,

| — | China, |
| --- | --- |

—

China,

| — | Latin American and the Caribbean (CELAC), |
| --- | --- |

—

Latin American and the Caribbean (CELAC),

| — | Africa, in particular West Africa |
| --- | --- |

—

Africa, in particular West Africa

Ongoing

PRES Trio

COM

EEAS

MS

| — | Overarching indicator 13 |
| --- | --- |

—

Overarching indicator 13

| — | Strengthened cooperation in the field of drugs with relevant partners |
| --- | --- |

—

Strengthened cooperation in the field of drugs with relevant partners

| — | Dialogues organised |
| --- | --- |

—

Dialogues organised

| — | Declarations agreed |
| --- | --- |

—

Declarations agreed

| — | Programmes and action plans implemented |
| --- | --- |

—

Programmes and action plans implemented

EEAS reporting

Mid-term review of EU Drugs Strategy

COM biennial progress report

EU reporting matrices

Implementation reports of the relevant action plans

| 39. | Improve the Dublin Group consultative mechanism through intensified EU coordination and participation, better implementation and dissemination of the recommendations of the Mini Dublin Group reports |
| --- | --- |

39.

Improve the Dublin Group consultative mechanism through intensified EU coordination and participation, better implementation and dissemination of the recommendations of the Mini Dublin Group reports

Ongoing

Dublin Group

COM

EEAS

MS

| — | Level of activity across Dublin Group structures including number of Dublin Group recommendations effectively implemented |
| --- | --- |

—

Level of activity across Dublin Group structures including number of Dublin Group recommendations effectively implemented

Dublin Group reports

| 40. | Hold an annual dialogue on EU and MS drugs-related assistance to third countries accompanied by a written update |
| --- | --- |

40.

Hold an annual dialogue on EU and MS drugs-related assistance to third countries accompanied by a written update

From 2014

COM

EEAS

MS

| — | Annual dialogue on funding held |
| --- | --- |

—

Annual dialogue on funding held

COM biennial progress report

MS reporting

EEAS reporting

Project and programme monitoring and evaluation system and reports

| 41. | Ensure that the promotion and protection of human rights are fully integrated in political dialogues and in the planning and implementation of relevant drugs-related programmes and projects including through the development of a human rights guidance and impact assessment tool |
| --- | --- |

41.

Ensure that the promotion and protection of human rights are fully integrated in political dialogues and in the planning and implementation of relevant drugs-related programmes and projects including through the development of a human rights guidance and impact assessment tool

Ongoing

COM

EEAS

MS

| — | Human rights effectively mainstreamed into EU external drugs action |
| --- | --- |

—

Human rights effectively mainstreamed into EU external drugs action

| — | Human rights guidance and assessment tool developed and implemented |
| --- | --- |

—

Human rights guidance and assessment tool developed and implemented

COM biennial progress report

COHOM annual human rights report

MS reporting

| 11. | Improve cohesiveness of EU approach and EU visibility in the United Nations (UN) and strengthen EU coordination with international bodies related to the drugs field |
| --- | --- |

11.

Improve cohesiveness of EU approach and EU visibility in the United Nations (UN) and strengthen EU coordination with international bodies related to the drugs field

| 42. | Contribute to shaping the agenda on international drugs policy, including through:






  (a) | action by EU and MS Delegations at the UN General Assembly and the Commission on Narcotic Drugs (CND); |
| --- | --- | --- |

42.

Contribute to shaping the agenda on international drugs policy, including through:

(a)

action by EU and MS Delegations at the UN General Assembly and the Commission on Narcotic Drugs (CND);

| (b) | preparation, coordination and adoption of EU common positions and joint resolutions in the UN General Assembly and the CND and ensuring that the EU speaks with one strong voice in these and other international fora; |
| --- | --- |

(b)

preparation, coordination and adoption of EU common positions and joint resolutions in the UN General Assembly and the CND and ensuring that the EU speaks with one strong voice in these and other international fora;

| (c) | the mid-term review process of the 2009 UN Political Declaration and Action Plan on International Cooperation towards an Integrated and Balanced Strategy to Counter the World Drug Problem; and |
| --- | --- |

(c)

the mid-term review process of the 2009 UN Political Declaration and Action Plan on International Cooperation towards an Integrated and Balanced Strategy to Counter the World Drug Problem; and

| (d) | the 2016 UN General Assembly Special Session on Drugs |
| --- | --- |

(d)

the 2016 UN General Assembly Special Session on Drugs

Ongoing

EEAS

PRES

MS

COM

Council

HDG

| — | Overarching indicator 13 |
| --- | --- |

—

Overarching indicator 13

| — | Effective promotion of EU policies in the UN, including at the CND |
| --- | --- |

—

Effective promotion of EU policies in the UN, including at the CND

| — | Number of EU common positions supported by other regions and international bodies |
| --- | --- |

—

Number of EU common positions supported by other regions and international bodies

| — | Frequency with which EU speaks with a single effective voice in international fora and in dialogues with third countries |
| --- | --- |

—

Frequency with which EU speaks with a single effective voice in international fora and in dialogues with third countries

| — | Level of successful adoption of EU resolutions at UN including at the CND |
| --- | --- |

—

Level of successful adoption of EU resolutions at UN including at the CND

| — | Outcome of the mid-term review of the 2009 UN Political Declaration and Action Plan on International Co-operation towards an Integrated and Balanced Strategy to Counter the World Drug Problem |
| --- | --- |

—

Outcome of the mid-term review of the 2009 UN Political Declaration and Action Plan on International Co-operation towards an Integrated and Balanced Strategy to Counter the World Drug Problem

| — | Adoption of an EU Joint Position Paper for the 2016 UNGASS and reflection of the EU positions in the UNGASS outcome |
| --- | --- |

—

Adoption of an EU Joint Position Paper for the 2016 UNGASS and reflection of the EU positions in the UNGASS outcome

EEAS reporting

Mid-term review of the EU Drugs Strategy

COM biennial progress report

Convergence indicator

Mid-term review

UNGASS outcome

| 43. | Strengthen partnerships with the UNODC, WHO UNAIDS and other relevant UN agencies, international and regional bodies and organisations and initiatives (such as the Council of Europe and the Paris Pact Initiative) |
| --- | --- |

43.

Strengthen partnerships with the UNODC, WHO UNAIDS and other relevant UN agencies, international and regional bodies and organisations and initiatives (such as the Council of Europe and the Paris Pact Initiative)

Ongoing

Council

EEAS

COM

PRES

HDG

| — | Overarching indicator 13 |
| --- | --- |

—

Overarching indicator 13

| — | Number of information exchanges and activities between the EU and relevant international and regional bodies and organisations and initiatives |
| --- | --- |

—

Number of information exchanges and activities between the EU and relevant international and regional bodies and organisations and initiatives

| — | Effectiveness of partnerships with relevant bodies |
| --- | --- |

—

Effectiveness of partnerships with relevant bodies

EEAS reporting

Mid-term review of the EU Drugs Strategy

COM biennial progress report

| 12. | Support the process for acceding countries, candidate countries, and potential candidates to adapt to and align with the EU acquis in the drugs field, through targeted assistance and monitoring |
| --- | --- |

12.

Support the process for acceding countries, candidate countries, and potential candidates to adapt to and align with the EU acquis in the drugs field, through targeted assistance and monitoring

| 44. | Provide targeted technical assistance, and other assistance and support as necessary, to acceding countries, candidate countries, and potential candidates to facilitate their adaptation to and alignment with the EU acquis in the drugs field |
| --- | --- |

44.

Provide targeted technical assistance, and other assistance and support as necessary, to acceding countries, candidate countries, and potential candidates to facilitate their adaptation to and alignment with the EU acquis in the drugs field

Ongoing

COM

MS

EMCDDA

Europol

Eurojust

Frontex

EEAS

| — | Increased compliance by countries with EU acquis |
| --- | --- |

—

Increased compliance by countries with EU acquis

| — | Number and quality of completed projects |
| --- | --- |

—

Number and quality of completed projects

| — | National Drugs Strategies and national drugs coordinating structures established |
| --- | --- |

—

National Drugs Strategies and national drugs coordinating structures established

COM biennial progress report

Acceding countries, candidate countries and potential candidates reports

5.   Information, research, monitoring and evaluation

Contribute to a better understanding of all aspects of the drugs phenomenon and of the impact of measures in order to provide sound and comprehensive evidence for policies and actions

| Objective | Action | Timetable | Responsible party | Indicator(s) | Data collection/assessment mechanisms |
| --- | --- | --- | --- | --- | --- |
| 13. | Ensure adequate investment in research, data collection, monitoring, evaluation and information exchange on all aspects of the drug phenomenon |

Objective

Action

Timetable

Responsible party

Indicator(s)

Data collection/assessment mechanisms

13.

Ensure adequate investment in research, data collection, monitoring, evaluation and information exchange on all aspects of the drug phenomenon

| 45. | Promote appropriate financing of EU-level drug-related multi-disciplinary research and studies including through EU related financial programmes (2014-2020) |
| --- | --- |

45.

Promote appropriate financing of EU-level drug-related multi-disciplinary research and studies including through EU related financial programmes (2014-2020)

2014-2016

MS

COM

EMCDDA

| — | Amount and type of EU funding provided across the different programme and projects |
| --- | --- |

—

Amount and type of EU funding provided across the different programme and projects

COM biennial progress report

| 46. | Ensure that EU-supported projects:






  (a) | take account of the priorities of the EU Drugs Strategy and Action Plan on Drugs; |
| --- | --- | --- |

46.

Ensure that EU-supported projects:

(a)

take account of the priorities of the EU Drugs Strategy and Action Plan on Drugs;

| (b) | take account of gaps in policy formulation; |
| --- | --- |

(b)

take account of gaps in policy formulation;

| (c) | deliver clear added value and ensure coherence and synergy; and |
| --- | --- |

(c)

deliver clear added value and ensure coherence and synergy; and

| (d) | avoid duplication with research under other programmes and bodies; |
| --- | --- |

(d)

avoid duplication with research under other programmes and bodies;

| (e) | take account of the importance of behavioural research and neuroscience |
| --- | --- |

(e)

take account of the importance of behavioural research and neuroscience

2014-2016

COM

EMCDDA

| — | The inclusion of the priorities of the EU Strategy and Action Plan on Drugs in the funding and assessment criteria of EU-funded drugs-related research |
| --- | --- |

—

The inclusion of the priorities of the EU Strategy and Action Plan on Drugs in the funding and assessment criteria of EU-funded drugs-related research

| — | Number, impact, complementarity and value of EU-funded drugs-related research grants and contracts awarded |
| --- | --- |

—

Number, impact, complementarity and value of EU-funded drugs-related research grants and contracts awarded

| — | Number of EU-funded drugs-related articles and research reports published in peer-reviewed journals with high impact factors |
| --- | --- |

—

Number of EU-funded drugs-related articles and research reports published in peer-reviewed journals with high impact factors

| — | Annual debate at the HDG on drug-related research projects funded by the EU |
| --- | --- |

—

Annual debate at the HDG on drug-related research projects funded by the EU

COM biennial progress report

Research project reports

EMCDDA Scientific Committee recommendations on research priorities

Science Citation Index and similar bibliometric tools

Strategic research agenda and projects stemming from the ERA-net on drug demand and supply reduction

| 47. | Promote scientific evaluations of policies and interventions at national, EU and international level |
| --- | --- |

47.

Promote scientific evaluations of policies and interventions at national, EU and international level

2013-2016

COM

MS

EMCDDA

| — | Overarching indicator 14 |
| --- | --- |

—

Overarching indicator 14

| — | Regular progress review to the Council and European Parliament on Strategy and Action Plan implementation |
| --- | --- |

—

Regular progress review to the Council and European Parliament on Strategy and Action Plan implementation

| — | External mid-term assessment of the Strategy/Action Plan completed — 2016 |
| --- | --- |

—

External mid-term assessment of the Strategy/Action Plan completed — 2016

| — | European guidelines for the evaluation of national drug strategies and action plans published |
| --- | --- |

—

European guidelines for the evaluation of national drug strategies and action plans published

| — | Delivery of dedicated studies into the effectiveness and impacts of EU and international drug policies |
| --- | --- |

—

Delivery of dedicated studies into the effectiveness and impacts of EU and international drug policies

| — | Completed evaluation of the implementation of the 2003 Council Recommendation on the prevention and reduction of health-related harm associated with drug dependence |
| --- | --- |

—

Completed evaluation of the implementation of the 2003 Council Recommendation on the prevention and reduction of health-related harm associated with drug dependence

EMCDDA reporting

COM biennial progress report

Mid-term assessment report of EU drugs strategy

EMCDDA reporting

EMCDDA Scientific Committee reporting

Reports of ALICE RAP and LINKSCH and ERA-net

Reitox national reports

| 14. | Maintain networking and cooperation and develop capacity within and across the EU’s knowledge infrastructure for information, research, monitoring and evaluation of drugs, particularly illicit drugs |
| --- | --- |

14.

Maintain networking and cooperation and develop capacity within and across the EU’s knowledge infrastructure for information, research, monitoring and evaluation of drugs, particularly illicit drugs

| 48. | In collaboration with relevant parties as appropriate, continue to provide comprehensive analyses of:






  (a) | the EU drugs situation; |
| --- | --- | --- |

48.

In collaboration with relevant parties as appropriate, continue to provide comprehensive analyses of:

(a)

the EU drugs situation;

| (b) | the dynamics of drug use within general populations and target groups; and |
| --- | --- |

(b)

the dynamics of drug use within general populations and target groups; and

| (c) | responses to drug use |
| --- | --- |

(c)

responses to drug use

Ongoing

EMCDDA

Europol

MS

| — | Overarching indicators 1-15 |
| --- | --- |

—

Overarching indicators 1-15

| — | Current deficits in the knowledge base established and an EU level framework developed to maximise analyses from current data holdings |
| --- | --- |

—

Current deficits in the knowledge base established and an EU level framework developed to maximise analyses from current data holdings

| — | Number of overviews and topic analyses on the drug situation |
| --- | --- |

—

Number of overviews and topic analyses on the drug situation

EMCDDA reporting

MS reporting

| 49. | Enhance training for those involved in responding to the drugs phenomenon |
| --- | --- |

49.

Enhance training for those involved in responding to the drugs phenomenon

2014-2016

MS

EMCDDA

CEPOL

| — | Number of initiatives at MS and EU level to train professionals in aspects of drug demand reduction and drug supply reduction |
| --- | --- |

—

Number of initiatives at MS and EU level to train professionals in aspects of drug demand reduction and drug supply reduction

| — | Number of initiatives at MS and EU level implemented to train professionals related to data collection and reporting of drug demand reduction and drug supply reduction |
| --- | --- |

—

Number of initiatives at MS and EU level implemented to train professionals related to data collection and reporting of drug demand reduction and drug supply reduction

MS reporting

EMCDDA training report

CEPOL annual report

Reitox annual reports

| 50. | Enhance data collection, research, analysis and reporting on:






  (a) | drug demand reduction; |
| --- | --- | --- |

50.

Enhance data collection, research, analysis and reporting on:

(a)

drug demand reduction;

| (b) | drug supply reduction; |
| --- | --- |

(b)

drug supply reduction;

| (c) | emerging trends, such as polydrug use and misuse of prescribed controlled medicines, that pose risks to health and safety; |
| --- | --- |

(c)

emerging trends, such as polydrug use and misuse of prescribed controlled medicines, that pose risks to health and safety;

| (d) | blood-borne viruses associated with drug use including but not limited to HIV and viral hepatitis, as well as sexually transmittable diseases and tuberculosis; |
| --- | --- |

(d)

blood-borne viruses associated with drug use including but not limited to HIV and viral hepatitis, as well as sexually transmittable diseases and tuberculosis;

| (e) | psychiatric and physical co-morbidity; |
| --- | --- |

(e)

psychiatric and physical co-morbidity;

| (f) | drug problems among prisoners and the availability and coverage of drug demand reduction interventions and services in prison settings; and |
| --- | --- |

(f)

drug problems among prisoners and the availability and coverage of drug demand reduction interventions and services in prison settings; and

| (g) | other drug-related consequences |
| --- | --- |

(g)

other drug-related consequences

Ongoing

MS

COM

EMCDDA

Europol

ECDC

EMA

| — | Increased availability and implementation of evidence-based and scientifically sound indicators on drug supply reduction and drug demand reduction |
| --- | --- |

—

Increased availability and implementation of evidence-based and scientifically sound indicators on drug supply reduction and drug demand reduction

| — | At MS level, extent of new research initiated on emerging trends such as polydrug use and the misuse of prescribed controlled medicines; blood-borne diseases associated with drug use including but not limited to HIV and viral hepatitis, as well as sexually transmittable diseases and tuberculosis; psychiatric and physical co-morbidity; and other drug-related consequences |
| --- | --- |

—

At MS level, extent of new research initiated on emerging trends such as polydrug use and the misuse of prescribed controlled medicines; blood-borne diseases associated with drug use including but not limited to HIV and viral hepatitis, as well as sexually transmittable diseases and tuberculosis; psychiatric and physical co-morbidity; and other drug-related consequences

| — | EU-wide study carried out on drug-related community intimidation and its impact on individuals, families and communities most affected and effective responses to it |
| --- | --- |

—

EU-wide study carried out on drug-related community intimidation and its impact on individuals, families and communities most affected and effective responses to it

| — | Adoption of evidence-based and scientifically sound indicators on drug problems among prisoners |
| --- | --- |

—

Adoption of evidence-based and scientifically sound indicators on drug problems among prisoners

EMCDDA reporting

MS reporting

Harmonised data reports from EU bodies including EMCDDA

EU SOCTA

| 51. | Improve the capacity to detect, assess and respond effectively to the emergence and use of new psychoactive substances and monitor the extent to which such new substances impact on the number and profile of users |
| --- | --- |

51.

Improve the capacity to detect, assess and respond effectively to the emergence and use of new psychoactive substances and monitor the extent to which such new substances impact on the number and profile of users

Ongoing

COM

MS

EMCDDA

Europol

| — | Overarching indicator 6 |
| --- | --- |

—

Overarching indicator 6

| — | Extent of new epidemiological, pharmacological and toxicological research initiated on new psychoactive substances and supported by MS and EU research programmes |
| --- | --- |

—

Extent of new epidemiological, pharmacological and toxicological research initiated on new psychoactive substances and supported by MS and EU research programmes

| — | Extent of information, best practice and intelligence exchange |
| --- | --- |

—

Extent of information, best practice and intelligence exchange

| — | Extent of sharing by toxicology laboratories and by research institutes of toxicological and health data analyses on new psychoactive substances |
| --- | --- |

—

Extent of sharing by toxicology laboratories and by research institutes of toxicological and health data analyses on new psychoactive substances

EMCDDA reporting

EMCDDA-Europol implementation report

Reports by laboratories and research institutes

Reitox national reports

| 52. | Strengthen efforts to share forensic science data, including laboratory reference standards, on new psychoactive substances, by enhancing co-operation through existing networks, such as the Drugs Working Group of the European Network of Forensic Science Institutes in the framework of the JHA Council conclusions on the vision for European Forensic Science 2020 |
| --- | --- |

52.

Strengthen efforts to share forensic science data, including laboratory reference standards, on new psychoactive substances, by enhancing co-operation through existing networks, such as the Drugs Working Group of the European Network of Forensic Science Institutes in the framework of the JHA Council conclusions on the vision for European Forensic Science 2020

2016

COM

MS

EMCDDA

| — | Overarching indicator 15 |
| --- | --- |

—

Overarching indicator 15

| — | Extent of sharing of forensic science data on new psychoactive substances |
| --- | --- |

—

Extent of sharing of forensic science data on new psychoactive substances

| — | Ease of access to laboratory reference standards by forensic science laboratories and institutes |
| --- | --- |

—

Ease of access to laboratory reference standards by forensic science laboratories and institutes

EMCDDA/Europol reporting

COM biennial progress report

| 53. | Improve the ability to identify, assess and respond at MS and EU levels to (a) behavioural changes in drug consumption and (b) to epidemic outbreaks |
| --- | --- |

53.

Improve the ability to identify, assess and respond at MS and EU levels to (a) behavioural changes in drug consumption and (b) to epidemic outbreaks

Ongoing

MS

EMCDDA

ECDC

EMA

| — | Number and effectiveness of new drug-related public health initiatives developed and implemented |
| --- | --- |

—

Number and effectiveness of new drug-related public health initiatives developed and implemented

| — | Number and effectiveness of existing initiatives that are adjusted to take account of drug consumption or epidemic outbreaks |
| --- | --- |

—

Number and effectiveness of existing initiatives that are adjusted to take account of drug consumption or epidemic outbreaks

| — | Number and impact of early warning reports, risk assessment and alerts |
| --- | --- |

—

Number and impact of early warning reports, risk assessment and alerts

Reitox national reports

Early Warning System reports

EMCDDA reporting

| 15. | Enhance dissemination of monitoring, research and evaluation results at EU and national level |
| --- | --- |

15.

Enhance dissemination of monitoring, research and evaluation results at EU and national level

| 54. | Member States continue to support EU monitoring and information exchange efforts, including cooperation with, and adequate support for, Reitox national focal points |
| --- | --- |

54.

Member States continue to support EU monitoring and information exchange efforts, including cooperation with, and adequate support for, Reitox national focal points

Ongoing

MS

EMCDDA

| — | Open-access outputs from EU-funded studies disseminated |
| --- | --- |

—

Open-access outputs from EU-funded studies disseminated

| — | Extent to which Reitox national focal points funding and other resources match requirements |
| --- | --- |

—

Extent to which Reitox national focal points funding and other resources match requirements

| — | Number and effectiveness of Reitox national focal points dissemination initiatives |
| --- | --- |

—

Number and effectiveness of Reitox national focal points dissemination initiatives

Web dissemination including OpenAire, Cordis

EMCDDA website

Reitox national reports

---

ANNEX 1

15 over-arching indicators for the EU Action Plan on Drugs 2013-2016 (existing reporting mechanisms)

| 1. | Percentage of population who use drugs currently (within last month), used drugs recently (within last year), and who have ever used (lifetime use) by drug and age group (EMCDDA General population survey) |
| --- | --- |

1.

Percentage of population who use drugs currently (within last month), used drugs recently (within last year), and who have ever used (lifetime use) by drug and age group (EMCDDA General population survey)

| 2. | Estimated trends in the prevalence of problem and injecting drug use (EMCDDA Problem drug use) |
| --- | --- |

2.

Estimated trends in the prevalence of problem and injecting drug use (EMCDDA Problem drug use)

| 3. | Trends in drug-induced deaths and mortality amongst drug users (according to national definitions) (EMCDDA Drug-related deaths) |
| --- | --- |

3.

Trends in drug-induced deaths and mortality amongst drug users (according to national definitions) (EMCDDA Drug-related deaths)

| 4. | Prevalence and incidence, among injecting drug users, of infectious diseases attributable to drug use, including HIV and viral hepatitis, sexually transmittable diseases and tuberculosis (EMCDDA Drug-related infectious diseases) |
| --- | --- |

4.

Prevalence and incidence, among injecting drug users, of infectious diseases attributable to drug use, including HIV and viral hepatitis, sexually transmittable diseases and tuberculosis (EMCDDA Drug-related infectious diseases)

| 5. | Trends in the age of first use of illicit drugs (European School Survey Project on Alcohol and Other Drugs (ESPAD), Health Behaviour in School-aged Children (HBSC) and General Population Drug Use Survey (EMCDDA Key epidemiological indicator)) |
| --- | --- |

5.

Trends in the age of first use of illicit drugs (European School Survey Project on Alcohol and Other Drugs (ESPAD), Health Behaviour in School-aged Children (HBSC) and General Population Drug Use Survey (EMCDDA Key epidemiological indicator))

| 6. | Trends in numbers of people entering drug treatment (EMCDDA Treatment demand) and the estimated total number of people in drug treatment (EMCDDA Treatment demand and health and social responses) |
| --- | --- |

6.

Trends in numbers of people entering drug treatment (EMCDDA Treatment demand) and the estimated total number of people in drug treatment (EMCDDA Treatment demand and health and social responses)

| 7. | Trends in number of and quantities of seized illicit drugs (EMCDDA Drug seizures: cannabis incl. herbal cannabis, heroin, cocaine, crack cocaine, amphetamine, methamphetamine, ecstasy, LSD and other substances) |
| --- | --- |

7.

Trends in number of and quantities of seized illicit drugs (EMCDDA Drug seizures: cannabis incl. herbal cannabis, heroin, cocaine, crack cocaine, amphetamine, methamphetamine, ecstasy, LSD and other substances)

| 8. | Trends in retail price and purity of illicit drugs (EMCDDA Price and purity: cannabis incl. herbal cannabis, heroin, cocaine, crack cocaine, amphetamine, methamphetamine, ecstasy, LSD, other substances and composition of drug tablets) |
| --- | --- |

8.

Trends in retail price and purity of illicit drugs (EMCDDA Price and purity: cannabis incl. herbal cannabis, heroin, cocaine, crack cocaine, amphetamine, methamphetamine, ecstasy, LSD, other substances and composition of drug tablets)

| 9. | Trends in the number of initial reports of drug law offences, by drug and type of offence (supply v use/possession) (EMCDDA Drug offences) |
| --- | --- |

9.

Trends in the number of initial reports of drug law offences, by drug and type of offence (supply v use/possession) (EMCDDA Drug offences)

| 10. | Prevalence of drug use amongst prisoners (EMCDDA Drug use in prisons) |
| --- | --- |

10.

Prevalence of drug use amongst prisoners (EMCDDA Drug use in prisons)

| 11. | Assessment of availability, coverage and quality of services and interventions in the areas of prevention, harm reduction, social integration and treatment (EMCDDA Health and social responses) |
| --- | --- |

11.

Assessment of availability, coverage and quality of services and interventions in the areas of prevention, harm reduction, social integration and treatment (EMCDDA Health and social responses)

| 12. | Evidence-based interventions on prevention, treatment, social integration and recovery and their expected impact on drug use prevalence and problem drug use (EMCDDA Best practice portal) |
| --- | --- |

12.

Evidence-based interventions on prevention, treatment, social integration and recovery and their expected impact on drug use prevalence and problem drug use (EMCDDA Best practice portal)

| 13. | Strong dialogue and cooperation, in the drugs-related field, with other regions, third countries, international organisations and other parties (External Mid-Term Evaluation of Strategy/Action Plan; EEAS reporting) |
| --- | --- |

13.

Strong dialogue and cooperation, in the drugs-related field, with other regions, third countries, international organisations and other parties (External Mid-Term Evaluation of Strategy/Action Plan; EEAS reporting)

| 14. | Developments in national drug strategies, evaluations, legislation, coordination mechanisms and public expenditure estimates in EU Member States (EMCDDA) |
| --- | --- |

14.

Developments in national drug strategies, evaluations, legislation, coordination mechanisms and public expenditure estimates in EU Member States (EMCDDA)

| 15. | Early warning system on new psychoactive substances (EMCDDA/Europol) |
| --- | --- |

15.

Early warning system on new psychoactive substances (EMCDDA/Europol)

---

ANNEX 2

Glossary of acronyms

| ALICE RAP | Addiction and Lifestyles in Contemporary Europe — Reframing Addictions Project |
| --- | --- |
| ASEAN | Association of South-East Asian Nations |
| CCWP | Council of the EU — Customs Cooperation Working Party |
| CELAC | Comunidad de Estados Latinoamericanos y Caribeños (Community of Latin American and Caribbean States) |
| CEPOL | European Police College |
| CICAD | La Comisión Interamericana para el Control del Abuso de Drogas (The Inter-American Drug Abuse Control Commission) |
| CND | Commission on Narcotic Drugs (UN) |
| COAFR | Council of the EU — Africa Working Party |
| COASI | Council of the EU — Asia-Oceania Working Party |
| COEST | Council of the EU — Working Party on Eastern Europe and Central Asia |
| COHOM | Council of the EU — Working Party on Human Rights |
| COLAT | Council of the EU — Working Party on Latin America |
| COM | European Union Commission |
| COSI | Council of the EU — Standing Committee on Operational Cooperation on Internal Security |
| COWEB | Council of the EU — Working Party on the Western Balkans Region |
| CUG | Council of the EU — Customs Union Group |
| ECDC | European Centre for Disease Prevention and Control |
| ECOWAS | Economic Community of West African States |
| EEAS | European External Action Service |
| EMA | European Medicines Agency |
| EMCDDA | European Monitoring Centre for Drugs and Drug Addiction |
| EMPACT | European Multidisciplinary Platform against Criminal Threats |
| ENFSI | European Network of Forensic Science Institutes |
| ERA-net | European Research Area — Network |
| ESPAD | European School Survey Project on Alcohol and Other Drugs |
| EU SOCTA | EU Serious and Organised Crime Threat Assessment |
| Frontex | European Agency for the Management of Operational Cooperation at the External Borders of the Member States of the European Union |
| HBSC | Health Behaviour in School-aged Children Survey |
| HDG | Council of the EU — Horizontal Working Group on Drugs |
| INCB | International Narcotics Control Board (UN) |
| JHA | Justice and Home Affairs |
| LINKSCH | The LINKSCH project is a comparative study of two major drug markets, cannabis and heroin, through the prism of the transit chains operating between Central Asia and the EU and those between North Africa and the EU |
| MS | Member State |
| PEN | UNODC/INCB developed Pre-Export Notification Online System |
| PICS | Precursors Incident Communication System |
| PRES | Rotating presidency of the Council of the European Union |
| PRES Trio | Grouping of three consecutive rotating presidencies of the Council of the European Union |
| Reitox | Réseau Européen d’Information sur les Drogues et les Toxicomanies |
| SOCTA | Serious and Organised Crime Threat Assessment |
| UN | United Nations |
| UNAIDS | Joint United Nations Programme on HIV/AIDS |
| UNGASS | United Nations General Assembly Special Session |
| UNODC | United Nations Office on Drugs and Crime |
| WCO | World Customs Organisation |
| WHO | World Health Organisation (UN) |

ALICE RAP

Addiction and Lifestyles in Contemporary Europe — Reframing Addictions Project

ASEAN

Association of South-East Asian Nations

CCWP

Council of the EU — Customs Cooperation Working Party

CELAC

Comunidad de Estados Latinoamericanos y Caribeños (Community of Latin American and Caribbean States)

CEPOL

European Police College

CICAD

La Comisión Interamericana para el Control del Abuso de Drogas (The Inter-American Drug Abuse Control Commission)

CND

Commission on Narcotic Drugs (UN)

COAFR

Council of the EU — Africa Working Party

COASI

Council of the EU — Asia-Oceania Working Party

COEST

Council of the EU — Working Party on Eastern Europe and Central Asia

COHOM

Council of the EU — Working Party on Human Rights

COLAT

Council of the EU — Working Party on Latin America

COM

European Union Commission

COSI

Council of the EU — Standing Committee on Operational Cooperation on Internal Security

COWEB

Council of the EU — Working Party on the Western Balkans Region

CUG

Council of the EU — Customs Union Group

ECDC

European Centre for Disease Prevention and Control

ECOWAS

Economic Community of West African States

EEAS

European External Action Service

EMA

European Medicines Agency

EMCDDA

European Monitoring Centre for Drugs and Drug Addiction

EMPACT

European Multidisciplinary Platform against Criminal Threats

ENFSI

European Network of Forensic Science Institutes

ERA-net

European Research Area — Network

ESPAD

European School Survey Project on Alcohol and Other Drugs

EU SOCTA

EU Serious and Organised Crime Threat Assessment

Frontex

European Agency for the Management of Operational Cooperation at the External Borders of the Member States of the European Union

HBSC

Health Behaviour in School-aged Children Survey

HDG

Council of the EU — Horizontal Working Group on Drugs

INCB

International Narcotics Control Board (UN)

JHA

Justice and Home Affairs

LINKSCH

The LINKSCH project is a comparative study of two major drug markets, cannabis and heroin, through the prism of the transit chains operating between Central Asia and the EU and those between North Africa and the EU

MS

Member State

PEN

UNODC/INCB developed Pre-Export Notification Online System

PICS

Precursors Incident Communication System

PRES

Rotating presidency of the Council of the European Union

PRES Trio

Grouping of three consecutive rotating presidencies of the Council of the European Union

Reitox

Réseau Européen d’Information sur les Drogues et les Toxicomanies

SOCTA

Serious and Organised Crime Threat Assessment

UN

United Nations

UNAIDS

Joint United Nations Programme on HIV/AIDS

UNGASS

United Nations General Assembly Special Session

UNODC

United Nations Office on Drugs and Crime

WCO

World Customs Organisation

WHO

World Health Organisation (UN)

---

European Commission

| 30.11.2013 | EN | Official Journal of the European Union | C 351/24 |
| --- | --- | --- | --- |

30.11.2013

EN

Official Journal of the European Union

C 351/24

---

Euro exchange rates (1)

29 November 2013

2013/C 351/02

1 euro =

| | Currency | Exchange rate |
| --- | --- | --- |
| USD | US dollar | 1,3611 |
| JPY | Japanese yen | 139,21 |
| DKK | Danish krone | 7,4589 |
| GBP | Pound sterling | 0,83275 |
| SEK | Swedish krona | 8,9075 |
| CHF | Swiss franc | 1,2298 |
| ISK | Iceland króna | |
| NOK | Norwegian krone | 8,3200 |
| BGN | Bulgarian lev | 1,9558 |
| CZK | Czech koruna | 27,391 |
| HUF | Hungarian forint | 301,10 |
| LTL | Lithuanian litas | 3,4528 |
| LVL | Latvian lats | 0,7030 |
| PLN | Polish zloty | 4,2060 |
| RON | Romanian leu | 4,4385 |
| TRY | Turkish lira | 2,7475 |
| AUD | Australian dollar | 1,4934 |
| CAD | Canadian dollar | 1,4394 |
| HKD | Hong Kong dollar | 10,5523 |
| NZD | New Zealand dollar | 1,6698 |
| SGD | Singapore dollar | 1,7082 |
| KRW | South Korean won | 1 440,32 |
| ZAR | South African rand | 13,8610 |
| CNY | Chinese yuan renminbi | 8,2956 |
| HRK | Croatian kuna | 7,6405 |
| IDR | Indonesian rupiah | 15 980,55 |
| MYR | Malaysian ringgit | 4,3905 |
| PHP | Philippine peso | 59,447 |
| RUB | Russian rouble | 45,1550 |
| THB | Thai baht | 43,644 |
| BRL | Brazilian real | 3,1587 |
| MXN | Mexican peso | 17,7743 |
| INR | Indian rupee | 84,9740 |

Currency

Exchange rate

USD

US dollar

1,3611

JPY

Japanese yen

139,21

DKK

Danish krone

7,4589

GBP

Pound sterling

0,83275

SEK

Swedish krona

8,9075

CHF

Swiss franc

1,2298

ISK

Iceland króna

NOK

Norwegian krone

8,3200

BGN

Bulgarian lev

1,9558

CZK

Czech koruna

27,391

HUF

Hungarian forint

301,10

LTL

Lithuanian litas

3,4528

LVL

Latvian lats

0,7030

PLN

Polish zloty

4,2060

RON

Romanian leu

4,4385

TRY

Turkish lira

2,7475

AUD

Australian dollar

1,4934

CAD

Canadian dollar

1,4394

HKD

Hong Kong dollar

10,5523

NZD

New Zealand dollar

1,6698

SGD

Singapore dollar

1,7082

KRW

South Korean won

1 440,32

ZAR

South African rand

13,8610

CNY

Chinese yuan renminbi

8,2956

HRK

Croatian kuna

7,6405

IDR

Indonesian rupiah

15 980,55

MYR

Malaysian ringgit

4,3905

PHP

Philippine peso

59,447

RUB

Russian rouble

45,1550

THB

Thai baht

43,644

BRL

Brazilian real

3,1587

MXN

Mexican peso

17,7743

INR

Indian rupee

84,9740

---

(1)  Source: reference exchange rate published by the ECB.

---

NOTICES FROM MEMBER STATES

| 30.11.2013 | EN | Official Journal of the European Union | C 351/25 |
| --- | --- | --- | --- |

30.11.2013

EN

Official Journal of the European Union

C 351/25

---

Information communicated by Member States regarding closure of fisheries

2013/C 351/03

In accordance with Article 35(3) of Council Regulation (EC) No 1224/2009 of 20 November 2009 establishing a Community control system for ensuring compliance with the rules of the common fisheries policy (1), a decision has been taken to close the fishery as set down in the following table:

| Date and time of closure | 29.10.2013 |
| --- | --- |
| Duration | 29.10.2013-31.12.2013 |
| Member State | The Netherlands |
| Stock or group of stocks | HER/2A47DX |
| Species | Herring (Clupea Harengus) |
| Zone | IV, VIId and in EU waters of IIa |
| Type(s) of fishing vessels | — |
| Reference number | 65/TQ40 |

Date and time of closure

29.10.2013

Duration

29.10.2013-31.12.2013

Member State

The Netherlands

Stock or group of stocks

HER/2A47DX

Species

Herring (Clupea Harengus)

Zone

IV, VIId and in EU waters of IIa

Type(s) of fishing vessels

—

Reference number

65/TQ40

---

(1)  OJ L 343, 22.12.2009, p. 1.

---

| 30.11.2013 | EN | Official Journal of the European Union | C 351/25 |
| --- | --- | --- | --- |

30.11.2013

EN

Official Journal of the European Union

C 351/25

---

Information communicated by Member States regarding closure of fisheries

2013/C 351/04

In accordance with Article 35(3) of Council Regulation (EC) No 1224/2009 of 20 November 2009 establishing a Community control system for ensuring compliance with the rules of the common fisheries policy (1), a decision has been taken to close the fishery as set down in the following table:

| Date and time of closure | 24.10.2013 |
| --- | --- |
| Duration | 24.10.2013-31.12.2013 |
| Member State | France |
| Stock or group of stocks | HER/4AB. |
| Species | Herring (Clupea Harengus) |
| Zone | EU and Norwegian waters of IV north of 53° 30′ N |
| Type(s) of fishing vessels | — |
| Reference number | 63/TQ40 |

Date and time of closure

24.10.2013

Duration

24.10.2013-31.12.2013

Member State

France

Stock or group of stocks

HER/4AB.

Species

Herring (Clupea Harengus)

Zone

EU and Norwegian waters of IV north of 53° 30′ N

Type(s) of fishing vessels

—

Reference number

63/TQ40

---

(1)  OJ L 343, 22.12.2009, p. 1.

---

| 30.11.2013 | EN | Official Journal of the European Union | C 351/26 |
| --- | --- | --- | --- |

30.11.2013

EN

Official Journal of the European Union

C 351/26

---

Information communicated by Member States regarding closure of fisheries

2013/C 351/05

In accordance with Article 35(3) of Council Regulation (EC) No 1224/2009 of 20 November 2009 establishing a Community control system for ensuring compliance with the rules of the common fisheries policy (1), a decision has been taken to close the fishery as set down in the following table:

| Date and time of closure | 15.11.2013 |
| --- | --- |
| Duration | 15.11.2013-31.12.2013 |
| Member State | European Union (All Member States) |
| Stock or group of stocks | COD/N3M |
| Species | Cod (Gadus Morhua) |
| Zone | NAFO 3M |
| Type(s) of fishing vessels | — |
| Reference number | 66/TQ40 |

Date and time of closure

15.11.2013

Duration

15.11.2013-31.12.2013

Member State

European Union (All Member States)

Stock or group of stocks

COD/N3M

Species

Cod (Gadus Morhua)

Zone

NAFO 3M

Type(s) of fishing vessels

—

Reference number

66/TQ40

---

(1)  OJ L 343, 22.12.2009, p. 1.

---

V Announcements

PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMMON COMMERCIAL POLICY

European Commission

| 30.11.2013 | EN | Official Journal of the European Union | C 351/27 |
| --- | --- | --- | --- |

30.11.2013

EN

Official Journal of the European Union

C 351/27

---

Notice of initiation of an expiry review and of partial interim reviews and an ex officio partial interim review of the anti-dumping measures applicable to imports of citric acid originating in the People's Republic of China

2013/C 351/06

Following the publication of a notice of impending expiry (1) of the anti-dumping measures in force on the imports of citric acid originating in the People's Republic of China, the European Commission (‘the Commission’) has received requests for review pursuant to Article 11(2) and (3) of Council Regulation (EC) No 1225/2009 of 30 November 2009 on protection against dumped imports from countries not members of the European Community (2) (‘the basic Regulation’).

In addition, the Commission has decided on its own initiative to initiate a partial interim review of the anti-dumping measures applicable to imports of citric acid originating in the People's Republic of China pursuant to Article 11(3) of the basic Regulation. The review is limited in scope to the examination of the form of the measure and of injury.

1.   Requests for reviews and ex officio initiation

1.1.   
  Request for an expiry review

The request for expiry review was lodged on 2 August 2013 by SA Citrique Belge and Jungbunzlauer Austria AG (‘the applicants’) on behalf of producers representing 100 % of the Union production of citric acid.

1.2.   
  Request for a partial interim review limited in scope to the examination of dumping as far as Laiwu Taihe Biochemistry Co. Ltd (‘Laiwu Taihe’) is concerned

The request for a partial interim review was lodged on 10 October 2013 by the same applicants on behalf of producers representing 100 % of the Union production of citric acid.

The partial interim review is limited in scope to the examination of dumping as far as Laiwu Taihe Biochemistry Co. Ltd (‘Laiwu Taihe’) is concerned.

1.3.   Ex officio partial interim review

The Commission has decided on its own initiative to initiate a partial interim review of the anti-dumping measures applicable to imports of citric acid originating in the People's Republic of China pursuant to Article 11(3) of the basic Regulation. The review is limited in scope to the examination of the form of the measure and of injury.

2.   Possibility to request a review under Article 11(3) of the basic Regulation

If any interested party considers that a review of the measures is warranted for other reasons that those covered by the current notice of initiation (e.g., recalculation of dumping margin), that party may request a review pursuant to Article 11(3) of the basic Regulation.

Parties wishing to request such a review may contact the Commission at the address given below.

If such requests are made in time and do not jeopardise the completion of the above reviews within the statutory deadline, the Commission will endeavour to consider them within the context of the present investigation.

3.   Product under review

The product subject to this review is citric acid and trisodium citrate dihydrate (‘the product under review’ or ‘citric acid’), currently falling within CN codes 2918 14 00 and ex 2918 15 00 and originating in the People’s Republic of China (‘PRC’), the country concerned.

4.   Existing measures

The measures currently in force are a definitive anti-dumping duty imposed by Council Regulation (EC) No 1193/2008 (3).

The Commission, by Decision 2008/899/EC (4), accepted price undertakings offered by seven Chinese exporting producers together with the China Chamber of Commerce of Metals, Minerals & Chemicals Importers & Exporters.

The Commission, by Decision 2012/501/EU (5), withdrew the undertaking offered by one exporting producer, i.e. Laiwu Taihe.

5.   Grounds for the reviews

5.1.   
  Grounds for the expiry review

The request is based on the grounds that the expiry of the measures would be likely to result in continuation of dumping and recurrence of injury to the Union industry.

5.1.1.   Allegation of likelihood of continuation of dumping

Since, in view of the provisions of Article 2(7) of the basic Regulation, the PRC (‘the country concerned’) is considered to be a non-market economy country, the applicants established normal value for the exporting producers from the PRC which were not granted market economy treatment during the investigation leading to the measures in force on the basis of the price in a market economy third country, namely Canada. For those companies which were granted market economy treatment during the investigation leading to the measures in force, normal value has been established on the basis of a constructed normal value (manufacturing costs, selling, general and administrative costs (SG&A) and profit) in the PRC in the alleged absence of representative domestic sales. The allegation of likelihood of continuation of dumping is based on a comparison of the normal value, as set out in preceding sentences, with the export price (at ex-works level) of the product under review when sold for export to the Union.

On this basis the dumping margins calculated are significant for the country concerned.

5.1.2.   Allegation of likelihood of recurrence of injury

The applicants allege the likelihood of recurrence of injury. In this respect the applicants have provided prima facie evidence that, should measures be allowed to lapse, the current import level of the product under review from the country concerned to the Union is likely to increase due to the existence of unused capacity in the country concerned, the existence of trade barriers for the country concerned in the USA, Brazil, Thailand and Ukraine and the attractiveness of the Union market. In addition, it is also alleged that the exports to other third countries are made at much lower prices than to the Union.

The applicants finally allege that the removal of injury has been mainly due to the existence of measures and that any recurrence of substantial imports at dumped prices from the country concerned would likely lead to a recurrence of injury to the Union industry should measures be allowed to lapse.

5.2.   
  Grounds for the partial interim review

The request pursuant to Article 11(3) is based on prima facie evidence, provided by the applicants, that, as far as Laiwu Taihe is concerned, and as far as dumping is concerned, the circumstances on the basis of which the existing measures were imposed have changed and that these changes are of a lasting nature.

The applicants provided prima facie evidence showing that since the last investigation period Laiwu Taihe had increased production capacity and enlarged its product range. The applicants also provided a dumping margin calculation based on a comparison between a constructed normal value (manufacturing costs, selling, general and administrative costs (SG&A) and profit) in the PRC in the alleged absence of representative domestic sales and Laiwu Taihe’s export price to the Union, indicating that the dumping margin appears to be higher than the current level of the measures.

Therefore, the applicants allege that the continued imposition of the measures at the existing level, which was based on the level of dumping previously established, appears to be insufficient to offset the effects of injurious dumping.

5.3.   
  Grounds for an ex officio partial interim review

The Commission has at its disposal sufficient prima facie evidence that, as far as the form of the measures and injury are concerned, the circumstances on the basis of which the existing measures were imposed have changed and that these changes are of a lasting nature.

In particular, the information at the disposal of the Commission appears to indicate that the cost variables, on which the non-injurious price has been based to calculate the minimum import price of the undertakings, have changed. Such changes have had a significant impact on the overall performance of the Union industry.

All these developments appear to be of a lasting nature and therefore substantiate the need to review the current form of the measures and to assess the injury findings. Based on the above, it appears that the continued imposition of measures at the existing level may no longer be appropriate to offset the effects of injurious dumping.

6.   Procedure

Having determined, after consulting the Advisory Committee, that sufficient evidence exists to justify the initiation of an expiry review, a partial interim review limited to the examination of the dumping margin for Laiwu Taihe and an ex officio partial interim review of the form of the measures and injury, the Commission hereby initiates reviews in accordance with Article 11(2) and (3) of the basic Regulation.

The expiry review will determine whether the expiry of the measures would be likely to lead to a continuation or recurrence of dumping of the product under review originating in the country concerned and a continuation or recurrence of injury to the Union industry.

The investigation will also assess the need for the continuation, removal or amendment of the existing measures.

6.1.1.   Investigating exporting producers

6.1.1.1.   Procedure for selecting exporting producers to be investigated in the PRC

In view of the potentially large number of exporting producers in the PRC involved in this expiry and partial interim review and in order to complete the investigation within the statutory time limits, the Commission may limit the exporting producers to be investigated to a reasonable number by selecting a sample (this process is also referred to as ‘sampling’). The sampling will be carried out in accordance with Article 17 of the basic Regulation.

In order to enable the Commission to decide whether sampling is necessary, and if so, to select a sample, all exporting producers, or representatives acting on their behalf, including the ones who did not cooperate in the investigation leading to the measures subject to the present review, are hereby requested to make themselves known to the Commission. These parties have to do so within 15 days of the date of publication of this notice in the Official Journal of the European Union, unless otherwise specified, by providing the Commission with the information on their company(ies) requested in Annex I to this notice.

In order to obtain the information it deems necessary for the selection of the sample of exporting producers, the Commission will also contact the authorities of the People’s Republic of China and may contact any known associations of exporting producers.

All interested parties wishing to submit any other relevant information regarding the selection of the sample, excluding the information requested above, must do so within 21 days of the publication of this notice in the Official Journal of the European Union, unless otherwise specified.

If a sample is necessary, the exporting producers may be selected based on the largest representative volume of exports to the Union which can reasonably be investigated within the time available. All known exporting producers, the authorities of the country concerned and associations of exporting producers will be notified by the Commission, via the authorities of the country concerned if appropriate, of the companies selected to be in the sample.

In order to obtain the information it deems necessary for its investigation with regard to exporting producers, the Commission will send questionnaires to the exporting producers selected to be in the sample, to any known association of exporting producers and to the authorities of the PRC.

All exporting producers selected to be in the sample and any known association of exporting producers will have to submit a completed questionnaire within 37 days from the date of notification of the sample selection, unless otherwise specified.

The questionnaire will request information on, inter alia, the structure of the exporting producer's company(ies), the activities of the company(ies) in relation to the product under review, the cost of production, the sales of the product under review on the domestic market of the country concerned and the sales of the product under review to the Union.

6.1.1.2.   Procedure for Laiwu Taihe

In order to obtain the information it deems necessary for its investigation with regard to Laiwu Taihe, the Commission will send a questionnaire to Laiwu Taihe.

Laiwu Taihe must submit the completed questionnaire within 37 days of the date of publication of this notice in the Official Journal of the European Union, unless otherwise specified.

The questionnaire will request information on, inter alia, the structure of the exporting producer's company, the activities of the company in relation to the product under review, the cost of production, the sales of the product under review on the domestic market of the country concerned and the sales of the product under review to the Union.

The Commission will also send a MET claim form to this company. Laiwu Taihe must submit the completed MET claim form within 21 days of the date of publication of this notice in the Official Journal of the European Union, unless otherwise specified. In accordance with Article 2(7)(b) of the basic Regulation, should Laiwu Taihe consider that market economy conditions prevail for them in respect of the manufacture and sale of the product under review, they may submit a properly substantiated claim to this effect (‘MET claim’). MET will be granted if the assessment of the MET claim shows that the criteria laid down in Article 2(7)(c) of the basic Regulation (6) are fulfilled. Should Laiwu Taihe be granted MET, its dumping margin will be calculated, to the extent possible and without prejudice to the use of facts available pursuant to Article 18 of the basic Regulation, by using their own normal value and export prices in accordance with Article 2(7)(b) of the basic Regulation.

6.1.2.   Selection of a market economy third country for the purpose of the expiry review and the partial interim review limited to dumping in respect of Laiwu Taihe

Subject to the provisions of Section 6.1.1.2 above, in accordance with Article 2(7)(a) of the basic Regulation, in the case of imports from the PRC, normal value will be determined on the basis of the price or constructed value in a market economy third country.

In the previous investigation Canada was used as a market economy third country for the purpose of establishing normal value in respect of the PRC. For the purpose of the current investigation, the Commission envisages using again Canada. Interested parties are hereby invited to comment on the appropriateness of this choice within 10 days of the date of publication of this notice in the Official Journal of the European Union.

6.1.3.   Investigating unrelated importers
   (7)
   (8)

Unrelated importers of the product under review from the PRC to the Union are invited to participate in this investigation.

In view of the potentially large number of unrelated importers involved in this expiry and partial interim review and in order to complete the investigation within the statutory time limits, the Commission may limit to a reasonable number the unrelated importers that will be investigated by selecting a sample (this process is also referred to as ‘sampling’). The sampling will be carried out in accordance with Article 17 of the basic Regulation.

In order to enable the Commission to decide whether sampling is necessary and, if so, to select a sample, all unrelated importers, or representatives acting on their behalf, including the ones who did not cooperate in the investigation leading to the measures subject to the present review, are hereby requested to make themselves known to the Commission. These parties must do so within 15 days of the date of publication of this notice in the Official Journal of the European Union, unless otherwise specified, by providing the Commission with the information on their company(ies) requested in Annex II to this notice.

In order to obtain information it deems necessary for the selection of the sample of unrelated importers, the Commission may also contact any known associations of importers.

All interested parties wishing to submit any other relevant information regarding the selection of the sample, excluding the information requested above, must do so within 21 days of the publication of this notice in the Official Journal of the European Union, unless otherwise specified.

If a sample is necessary, the importers may be selected based on the largest representative volume of sales of the product under review in the Union which can reasonably be investigated within the time available. All known unrelated importers and associations of importers will be notified by the Commission of the companies selected to be in the sample.

In order to obtain the information it deems necessary for its investigation, the Commission will send questionnaires to the sampled unrelated importers. These parties must submit a completed questionnaire within 37 days from the date of the notification of the sample selection, unless otherwise specified.

The questionnaire will request information on, inter alia, the structure of their company(ies), the activities of the company(ies) in relation to the product under review and the sales of the product under review.

6.2.   
  Procedure for the determination of a likelihood of continuation or recurrence of injury

In order to establish whether there is a likelihood of a continuation or recurrence of injury to the Union industry, Union producers of the product under review are invited to participate in the Commission investigation.

6.2.1.   Investigating Union producers

In order to obtain the information it deems necessary for its investigation with regard to Union producers, the Commission will send questionnaires to known Union producers: Citrique Belge SA and Jungbunzlauer Austria AG.

The aforementioned Union producers must submit the completed questionnaire within 37 days of the date of publication of this notice in the Official Journal of the European Union, unless otherwise specified.

The questionnaire will request information on, inter alia, the structure of their company(ies) and the financial and economic situation of the company(ies).

Any Union producer and association of Union producers not listed above is invited to contact the Commission, preferably by e-mail, immediately but no later than 15 days after the publication of this notice in the Official Journal of the European Union, unless otherwise specified, in order to make itself known and request a questionnaire.

6.3.   
  Procedure for the assessment of Union interest

Should the likelihood of continuation or recurrence of dumping and injury be confirmed, a decision will be reached, pursuant to Article 21 of the basic Regulation, as to whether maintaining anti-dumping measures, amended as necessary as a result of the interim reviews, would not be against the Union interest. Union producers, importers and their representative associations, users and their representative associations, and representative consumer organisations are invited to make themselves known within 15 days of the date of publication of this notice in the Official Journal of the European Union, unless otherwise specified. In order to participate in the investigation, the representative consumer organisations have to demonstrate, within the same deadline, that there is an objective link between their activities and the product under review.

Parties that make themselves known within the above deadline may provide the Commission with information on the Union interest within 37 days of the date of publication of this notice in the Official Journal of the European Union, unless otherwise specified. This information may be provided either in a free format or by completing a questionnaire prepared by the Commission. In any case, information submitted pursuant to Article 21 will only be taken into account if supported by factual evidence at the time of submission.

6.4.   
  Other written submissions

Subject to the provisions of this notice, all interested parties are hereby invited to make their views known, submit information and provide supporting evidence. Unless otherwise specified, this information and supporting evidence must reach the Commission within 37 days of the date of publication of this notice in the Official Journal of the European Union.

6.5.   
  Possibility to be heard by the Commission investigation services

All interested parties may request to be heard by the Commission investigation services. Any request to be heard must be made in writing and must specify the reasons for the request. For hearings on issues pertaining to the initial stage of the investigation, the request must be submitted within 15 days of the date of publication of this notice in the Official Journal of the European Union. Thereafter, a request to be heard must be submitted within the specific deadlines set by the Commission in its communication with the parties.

6.6.   
  Instructions for making written submissions and sending completed questionnaires and correspondence

All written submissions, including the information requested in this notice, completed questionnaires and correspondence provided by interested parties for which confidential treatment is requested shall be labelled ‘Limited’ (9).

Interested parties providing ‘Limited’ information are required to furnish non-confidential summaries of it pursuant to Article 19(2) of the basic Regulation, which will be labelled ‘For inspection by interested parties’. These summaries must be sufficiently detailed to permit a reasonable understanding of the substance of the information submitted in confidence. If an interested party providing confidential information does not furnish a non-confidential summary of it in the requested format and quality, such information may be disregarded.

Interested parties are required to make all submissions and requests in electronic format (non-confidential submissions via e-mail, confidential ones on CD-R/DVD), and must indicate their name, address, e-mail address, telephone and fax numbers. However, any powers of attorney, signed certifications, and any updates thereof, accompanying MET claim forms or questionnaire replies must be submitted on paper, i.e. by post or by hand, at the address below. If an interested party cannot provide its submissions and requests in electronic format, it must immediately contact the Commission in compliance with Article 18(2) of the basic Regulation. For further information concerning correspondence with the Commission, interested parties may consult the relevant web page on the website of the Directorate-General for Trade: http://ec.europa.eu/trade/tackling-unfair-trade/trade-defence

Commission address for correspondence:

| European Commission |
| --- |
| Directorate-General for Trade |
| Directorate H |
| Office: N-105 08/020 |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |
| Fax +32 22956505 |
| E-mail: TRADE-CITRIC-ACID-DUMPING@ec.europa.eu |
| TRADE-CITRIC-ACID-INJURY@ec.europa.eu |

European Commission

Directorate-General for Trade

Directorate H

Office: N-105 08/020

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

Fax +32 22956505

E-mail: TRADE-CITRIC-ACID-DUMPING@ec.europa.eu

TRADE-CITRIC-ACID-INJURY@ec.europa.eu

7.   Non-cooperation

In cases where any interested party refuses access to or does not provide the necessary information within the time limits, or significantly impedes the investigation, findings, affirmative or negative, may be made on the basis of facts available, in accordance with Article 18 of the basic Regulation.

Where it is found that any interested party has supplied false or misleading information, the information may be disregarded and use may be made of facts available.

If an interested party does not cooperate or cooperates only partially and findings are therefore based on facts available in accordance with Article 18 of the basic Regulation, the result may be less favourable to that party than if it had cooperated.

8.   Hearing Officer

Interested parties may request the intervention of the Hearing Officer for the Directorate-General for Trade. The Hearing Officer acts as an interface between the interested parties and the Commission investigation services. The Hearing Officer reviews requests for access to the file, disputes regarding the confidentiality of documents, requests for extension of time limits and requests by third parties to be heard. The Hearing Officer may organise a hearing with an individual interested party and mediate to ensure that the interested parties' rights of defence are being fully exercised.

A request for a hearing with the Hearing Officer should be made in writing and should specify the reasons for the request. For hearings on issues pertaining to the initial stage of the investigation, the request must be submitted within 15 days of the date of publication of this notice in the Official Journal of the European Union. Thereafter, a request to be heard must be submitted within specific deadlines set by the Commission in its communication with the parties.

The Hearing Officer will also provide opportunities for a hearing involving parties to take place which would allow different views to be presented and rebuttal arguments offered on issues pertaining, among other things, to the likelihood of a continuation or recurrence of dumping and injury, dumping, injury and Union interest.

For further information and contact details interested parties may consult the Hearing Officer's web pages on DG Trade's website: http://ec.europa.eu/commission_2010-2014/degucht/contact/hearing-officer/

9.   Schedule of the investigation

The investigation will be concluded, pursuant to Article 11(5) of the basic Regulation, within 15 months of the date of the publication of this notice in the Official Journal of the European Union.

10.   Processing of personal data

Any personal data collected in this investigation will be treated in accordance with Regulation (EC) No 45/2001 of the European Parliament and of the Council on the protection of individuals with regard to the processing of personal data by the Community institutions and bodies and on the free movement of such data (10).

---

(1)  OJ C 60, 1.3.2013, p. 9.

(2)  OJ L 343, 22.12.2009, p. 51.

(3)  OJ L 323, 3.12.2008, p. 1.

(4)  OJ L 323, 3.12.2008, p. 62.

(5)  OJ L 244, 8.9.2012, p. 27.

(6)  The exporting producer has to demonstrate in particular that: (i) business decisions and costs are made in response to market conditions and without significant State interference; (ii) firms have one clear set of basic accounting records which are independently audited in line with international accounting standards and are applied for all purposes; (iii) there are no significant distortions carried over from the former non-market economy system; (iv) bankruptcy and property laws guarantee legal certainty and stability, and (v) exchange rate conversions are carried out at market rates.

(7)  Only importers not related to exporting producers can be sampled. Importers that are related to exporting producers have to fill in Annex I to the questionnaire for these exporting producers. For the definition of a related party, see footnote 3 of Annex II to this notice.

(8)  The data provided by unrelated importers may also be used in relation to aspects of this investigation other than the determination of dumping.

(9)  A ‘Limited’ document is a document which is considered confidential pursuant to Article 19 of Council Regulation (EC) No 1225/2009 (OJ L 343, 22.12.2009, p. 51) and Article 6 of the WTO Agreement on Implementation of Article VI of the GATT 1994 (Anti-Dumping Agreement). It is also a document protected pursuant to Article 4 of Regulation (EC) No 1049/2001 of the European Parliament and of the Council (OJ L 145, 31.5.2001, p. 43).

(10)  OJ L 8, 12.1.2001, p. 1.

---

ANNEX I

Image

Image

---

ANNEX II

Image

Image

---

PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY

European Commission

| 30.11.2013 | EN | Official Journal of the European Union | C 351/37 |
| --- | --- | --- | --- |

30.11.2013

EN

Official Journal of the European Union

C 351/37

---

Prior notification of a concentration

(Case COMP/M.7018 — Telefónica Deutschland/E-Plus)

(Text with EEA relevance)

2013/C 351/07

| 1. | On 31 October 2013, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Telefónica Deutschland Holding AG (‘Telefónica Deutschland’), a German subsidiary of Telefónica SA (Spain), acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the assets, liabilities and contractual positions of and in relation to the current business of E-Plus Mobilfunk GmbH & Co. KG (‘E-Plus’, Germany) by way of a purchase of shares. |
| --- | --- |

1.

On 31 October 2013, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Telefónica Deutschland Holding AG (‘Telefónica Deutschland’), a German subsidiary of Telefónica SA (Spain), acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the assets, liabilities and contractual positions of and in relation to the current business of E-Plus Mobilfunk GmbH & Co. KG (‘E-Plus’, Germany) by way of a purchase of shares.

| 2. | The business activities of the undertakings concerned are:






  — | Telefónica Deutschland is a mobile network operator active in Germany. It provides wireless telecommunication services such as voice, SMS, MMS and mobile data services as well as, to a lesser extent, fixed line telecommunication services, to end customers in Germany. Telefónica Deutschland also provides mobile call origination services, mobile call termination services, wholesale network access services, international roaming services and other mobile telecommunications services, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

Telefónica Deutschland is a mobile network operator active in Germany. It provides wireless telecommunication services such as voice, SMS, MMS and mobile data services as well as, to a lesser extent, fixed line telecommunication services, to end customers in Germany. Telefónica Deutschland also provides mobile call origination services, mobile call termination services, wholesale network access services, international roaming services and other mobile telecommunications services,

| — | E-Plus is also a mobile network operator active in Germany. E-Plus provides wireless telecommunications services such as voice, SMS, MMS and mobile data services to end customers in Germany. E-Plus also provides mobile call origination services, mobile call termination services, wholesale network access services, international roaming services and other mobile telecommunications services. |
| --- | --- |

—

E-Plus is also a mobile network operator active in Germany. E-Plus provides wireless telecommunications services such as voice, SMS, MMS and mobile data services to end customers in Germany. E-Plus also provides mobile call origination services, mobile call termination services, wholesale network access services, international roaming services and other mobile telecommunications services.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope the EC Merger Regulation. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope the EC Merger Regulation. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.7018 — Telefónica Deutschland/E-Plus, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.7018 — Telefónica Deutschland/E-Plus, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘EC Merger Regulation’).

---

| 30.11.2013 | EN | Official Journal of the European Union | C 351/38 |
| --- | --- | --- | --- |

30.11.2013

EN

Official Journal of the European Union

C 351/38

---

Prior notification of a concentration

(Case COMP/M.7023 — Publicis/Omnicom)

(Text with EEA relevance)

2013/C 351/08

| 1. | On 25 November 2013, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Publicis Groupe SA (‘Publicis’, France) and Omnicom Group, Inc. (‘Omnicom’, U.S.A.) enter into a full merger within the meaning of Article 3(1)(a) of the Merger Regulation. |
| --- | --- |

1.

On 25 November 2013, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Publicis Groupe SA (‘Publicis’, France) and Omnicom Group, Inc. (‘Omnicom’, U.S.A.) enter into a full merger within the meaning of Article 3(1)(a) of the Merger Regulation.

| 2. | The business activities of the undertakings concerned are:






  — | for Publicis: international communications and advertising group, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for Publicis: international communications and advertising group,

| — | for Omnicom: global advertising, marketing and corporate communications company. |
| --- | --- |

—

for Omnicom: global advertising, marketing and corporate communications company.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope the EC Merger Regulation. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope the EC Merger Regulation. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.7023 — Publicis/Omnicom, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.7023 — Publicis/Omnicom, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘EC Merger Regulation’).

---

| 30.11.2013 | EN | Official Journal of the European Union | C 351/39 |
| --- | --- | --- | --- |

30.11.2013

EN

Official Journal of the European Union

C 351/39

---

Prior notification of a concentration

(Case COMP/M.7068 — Goldman Sachs/Kingdom of Denmark/DONG Energy)

Candidate case for simplified procedure

(Text with EEA relevance)

2013/C 351/09

| 1. | On 26 November 2013, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the Kingdom of Denmark (Denmark) and the Goldman Sachs Group, Inc. (‘Goldman Sachs’, USA) acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control over DONG Energy A/S (‘DONG’, Denmark) by way of a purchase of shares. The Kingdom of Denmark has currently sole control over DONG. |
| --- | --- |

1.

On 26 November 2013, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the Kingdom of Denmark (Denmark) and the Goldman Sachs Group, Inc. (‘Goldman Sachs’, USA) acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control over DONG Energy A/S (‘DONG’, Denmark) by way of a purchase of shares. The Kingdom of Denmark has currently sole control over DONG.

| 2. | The business activities of the undertakings concerned are:






  — | for Kingdom of Denmark: active inter alia in energy markets via DONG, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for Kingdom of Denmark: active inter alia in energy markets via DONG,

| — | for Goldman Sachs: active globally in investment banking, institutional client services, investing and lending and investment management, |
| --- | --- |

—

for Goldman Sachs: active globally in investment banking, institutional client services, investing and lending and investment management,

| — | for DONG: active in Northern Europe in the following markets: oil and natural gas exploration and production; development, construction and operation of offshore wind farms; electricity and heat generation from power plants; natural gas and electricity trading; and the sale and distribution of electricity and natural gas. |
| --- | --- |

—

for DONG: active in Northern Europe in the following markets: oil and natural gas exploration and production; development, construction and operation of offshore wind farms; electricity and heat generation from power plants; natural gas and electricity trading; and the sale and distribution of electricity and natural gas.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the EC Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the EC Merger Regulation (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the EC Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the EC Merger Regulation (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.7068 — Goldman Sachs/Kingdom of Denmark/DONG Energy, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| MADO 1 |
| 1210 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.7068 — Goldman Sachs/Kingdom of Denmark/DONG Energy, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

MADO 1

1210 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘EC Merger Regulation’).

(2)  OJ C 56, 5.3.2005, p. 32 (‘Notice on a simplified procedure’).

---